<html lang="en" class="pb-page js" data-request-id="94d63f5a762df1db-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d63f5a762df1db-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/E7Sol0qxQVcT9tP6HrX62GQIHd276eVye0nIKnpC2jGw1nrQk9yzAl8T-ANuQmlKxmsr0H64aojw3qfgMQ1Onw=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Ofatumumab versus Teriflunomide in Multiple Sclerosis | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d63f5a762df1db-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.7557751197910817"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="Specialties" content="Neurology/Neurosurgery">
<meta name="articleType" content="Original Article">
<meta name="articleCategory" content="Research">
<meta name="topics" content="Multiple Sclerosis"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa1917246","title":"Ofatumumab versus Teriflunomide in Multiple Sclerosis","category":"Research","type":"Original Article","topics":"Multiple Sclerosis","specialties":"Neurology/Neurosurgery","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2020-08-06T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"Specialties\" content\u003d\"Neurology/Neurosurgery\"/\u003e\n\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e\n\u003cmeta name\u003d\"topics\" content\u003d\"Multiple Sclerosis\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa1917246","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":[]};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d63f5a762df1db-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Ofatumumab versus Teriflunomide in Multiple Sclerosis"><meta name="dc.Creator" content="Stephen L. Hauser"><meta name="dc.Creator" content="Amit Bar-Or"><meta name="dc.Creator" content="Jeffrey A. Cohen"><meta name="dc.Creator" content="Giancarlo Comi"><meta name="dc.Creator" content="Jorge Correale"><meta name="dc.Creator" content="Patricia K. Coyle"><meta name="dc.Creator" content="Anne H. Cross"><meta name="dc.Creator" content="Jerome de Seze"><meta name="dc.Creator" content="David Leppert"><meta name="dc.Creator" content="Xavier Montalban"><meta name="dc.Creator" content="Krzysztof Selmaj"><meta name="dc.Creator" content="Heinz Wiendl"><meta name="dc.Creator" content="Cecile Kerloeguen"><meta name="dc.Creator" content="Roman Willi"><meta name="dc.Creator" content="Bingbing Li"><meta name="dc.Creator" content="Algirdas Kakarieka"><meta name="dc.Creator" content="Davorka Tomic"><meta name="dc.Creator" content="Alexandra Goodyear"><meta name="dc.Creator" content="Ratnakar Pingili"><meta name="dc.Creator" content="Dieter A. Häring"><meta name="dc.Creator" content="Krishnan Ramanathan"><meta name="dc.Creator" content="Martin Merschhemke"><meta name="dc.Creator" content="Ludwig Kappos"><meta name="dc.Description" content="Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and B-cell activation. The relative ..."><meta name="Description" content="Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and B-cell activation. The relative ..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2020-08-06"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa1917246"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202008063830613"><meta name="dc.Language" content="EN"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2020 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa1917246">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa1917246">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa1917246">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM">
        <meta property="og:title" content="Ofatumumab versus Teriflunomide in Multiple Sclerosis | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa1917246">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/fb4af6fb-f4bc-4618-856f-84a6dc6f5677/nejmoa1917246_f1.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/fb4af6fb-f4bc-4618-856f-84a6dc6f5677/nejmoa1917246_f1.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively depletes B cells.
Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and B-cell
activation. The relative ...">
        <meta name="twitter:description" content="Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively depletes B cells.
Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and B-cell
activation. The relative ...">
    


    
    
        <meta property="og:image:width" content="2276">
    


    
    
        <meta property="og:image:height" content="3438">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="publication_doi" content="10.1056/NEJMoa1917246">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa1917246">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;issue:issue:doi\:10.1056/nejm_2020.383.issue-6;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:doi\:10.1056/NEJMoa1917246;wgroup:string:MMS NextGen Website Group;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms">
        <link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa1917246" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa1917246" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa1917246" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa1917246" class="inputDoi"><input type="hidden" value="S.L. Hauser and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2020;383:546-557" class="inputCitation"><input type="hidden" value="08-05-2020" class="inputEPubDate"><input type="hidden" value="August 2020" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Ofatumumab versus Teriflunomide in Multiple Sclerosis" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d63f5a762df1db-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Ofatumumab versus Teriflunomide in Multiple Sclerosis</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Stephen L.</span> <span property="familyName">Hauser</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-4932-4001" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-4932-4001</a></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Amit</span> <span property="familyName">Bar-Or</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jeffrey A.</span> <span property="familyName">Cohen</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Giancarlo</span> <span property="familyName">Comi</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jorge</span> <span property="familyName">Correale</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Patricia K.</span> <span property="familyName">Coyle</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Anne H.</span> <span property="familyName">Cross</span>, <span property="honorificSuffix">M.D.</span></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+16</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jerome</span> <span property="familyName">de Seze</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">David</span> <span property="familyName">Leppert</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Xavier</span> <span property="familyName">Montalban</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Krzysztof</span> <span property="familyName">Selmaj</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Heinz</span> <span property="familyName">Wiendl</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Cecile</span> <span property="familyName">Kerloeguen</span>, <span property="honorificSuffix">M.Sc.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Roman</span> <span property="familyName">Willi</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Bingbing</span> <span property="familyName">Li</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Algirdas</span> <span property="familyName">Kakarieka</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Davorka</span> <span property="familyName">Tomic</span>, <span property="honorificSuffix">D.V.M.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Alexandra</span> <span property="familyName">Goodyear</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ratnakar</span> <span property="familyName">Pingili</span>, <span property="honorificSuffix">M.B., B.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Dieter A.</span> <span property="familyName">Häring</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Krishnan</span> <span property="familyName">Ramanathan</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Martin</span> <span property="familyName">Merschhemke</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Ludwig</span> <span property="familyName">Kappos</span>, <span property="honorificSuffix">M.D.</span></span></span>, for <span property="author" typeof="Person" role="listitem">the ASCLEPIOS I and ASCLEPIOS II Trial Groups<sup><a href="#fn2" role="doc-noteref">*</a></sup></span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-16</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">August 5, 2020</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2020<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">383</span></span>:<span property="pageStart">546</span>-<span property="pageEnd">557</span></div><div class="doi">DOI: 10.1056/NEJMoa1917246</div><div class="core-enumeration"><a href="/toc/nejm/383/6"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">383</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">6</span></span></a></div><div><a href="#tab-information">Copyright © 2020</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DStephen%2BL.%2BHauser%252C%2BAmit%2BBar-Or%252C%2BJeffrey%2BA.%2BCohen%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D383%26issueNum%3D6%26contentID%3D10.1056%252FNEJMoa1917246%26title%3DOfatumumab%2Bversus%2BTeriflunomide%2Bin%2BMultiple%2BSclerosis%26publicationDate%3D08%252F06%252F2020" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa1917246" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DStephen%2BL.%2BHauser%252C%2BAmit%2BBar-Or%252C%2BJeffrey%2BA.%2BCohen%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D383%26issueNum%3D6%26contentID%3D10.1056%252FNEJMoa1917246%26title%3DOfatumumab%2Bversus%2BTeriflunomide%2Bin%2BMultiple%2BSclerosis%26publicationDate%3D08%252F06%252F2020" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/85bae4f8-3964-4ece-8ba3-d85bcda19c48/nejmoa1917246.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa1917246.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa1917246" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa1917246" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa1917246.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and B-cell activation. The relative effects of these two drugs in patients with multiple sclerosis are not known.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">In two double-blind, double-dummy, phase 3 trials, we randomly assigned patients with relapsing multiple sclerosis to receive subcutaneous ofatumumab (20 mg every 4 weeks after 20-mg loading doses at days 1, 7, and 14) or oral teriflunomide (14 mg daily) for up to 30 months. The primary end point was the annualized relapse rate. Secondary end points included disability worsening confirmed at 3 months or 6 months, disability improvement confirmed at 6 months, the number of gadolinium-enhancing lesions per T1-weighted magnetic resonance imaging (MRI) scan, the annualized rate of new or enlarging lesions on T2-weighted MRI, serum neurofilament light chain levels at month 3, and change in brain volume.</div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">Overall, 946 patients were assigned to receive ofatumumab and 936 to receive teriflunomide; the median follow-up was 1.6 years. The annualized relapse rates in the ofatumumab and teriflunomide groups were 0.11 and 0.22, respectively, in trial 1 (difference, −0.11; 95% confidence interval [CI], −0.16 to −0.06; P&lt;0.001) and 0.10 and 0.25 in trial 2 (difference, −0.15; 95% CI, −0.20 to −0.09; P&lt;0.001). In the pooled trials, the percentage of patients with disability worsening confirmed at 3 months was 10.9% with ofatumumab and 15.0% with teriflunomide (hazard ratio, 0.66; P=0.002); the percentage with disability worsening confirmed at 6 months was 8.1% and 12.0%, respectively (hazard ratio, 0.68; P=0.01); and the percentage with disability improvement confirmed at 6 months was 11.0% and 8.1% (hazard ratio, 1.35; P=0.09). The number of gadolinium-enhancing lesions per T1-weighted MRI scan, the annualized rate of lesions on T2-weighted MRI, and serum neurofilament light chain levels, but not the change in brain volume, were in the same direction as the primary end point. Injection-related reactions occurred in 20.2% in the ofatumumab group and in 15.0% in the teriflunomide group (placebo injections). Serious infections occurred in 2.5% and 1.8% of the patients in the respective groups.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">Among patients with multiple sclerosis, ofatumumab was associated with lower annualized relapse rates than teriflunomide. (Funded by Novartis; ASCLEPIOS I and II ClinicalTrials.gov numbers, <a href="http://clinicaltrials.gov/show/NCT02792218" target="_blank">NCT02792218</a> and <a href="http://clinicaltrials.gov/show/NCT02792231" target="_blank">NCT02792231</a>.)</div></section></section></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">The pathophysiology of multiple sclerosis involves B cells. Anti-CD20 monoclonal antibodies that induce B-cell depletion, such as rituximab and ocrelizumab, are effective disease-modifying therapies for multiple sclerosis.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1 r2 r3 r4" id="body-ref-r4-1" href-manipulated="true">1-4</a></sup> Ofatumumab, a fully human antibody that is used to treat chronic leukemia, binds to a region distinct from that of other anti-CD20 antibodies, including the smaller and the larger loop of CD20 receptors.<sup><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5" id="body-ref-r5-1" href-manipulated="true" aria-label="Reference 5">5</a></sup> In experimental models, a high binding affinity and slow off-rate (slow dissociation of the binding between ofatumumab and the CD20 receptor in B cells) result in efficient B-cell lysis, mediated through complement-dependent and, to a lesser extent, antibody-dependent cytotoxicity.<sup><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5 r6 r7" id="body-ref-r7" href-manipulated="true">5-7</a></sup> In patients with multiple sclerosis, ofatumumab can be given at lower doses<sup><a href="#core-r8" role="doc-biblioref" data-xml-rid="r8 r9" id="body-ref-r9-1" href-manipulated="true">8,9</a></sup> than those studied in chronic lymphocytic leukemia and rheumatoid arthritis,<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10 r11 r12" id="body-ref-r12-1" href-manipulated="true">10-12</a></sup> and ofatumumab can be administered subcutaneously by the patient after initial doses are given under medical supervision.<sup><a href="#core-r8" role="doc-biblioref" data-xml-rid="r8" id="body-ref-r8-2" href-manipulated="true" aria-label="Reference 8">8</a></sup> Experimental models have shown that there may be more direct access to lymph nodes through the lymphatic system with subcutaneous administration than with intravenous infusion,<sup><a href="#core-r13" role="doc-biblioref" data-xml-rid="r13 r14" id="body-ref-r14" href-manipulated="true">13,14</a></sup> but this has not been tested under clinical conditions. On treatment cessation, B-cell repletion and reconstitution of humoral immunity have been reported to occur faster with ofatumumab than with other intravenously administered B-cell–targeted therapies.<sup><a href="#core-r15" role="doc-biblioref" data-xml-rid="r15 r16 r17" id="body-ref-r17" href-manipulated="true">15-17</a></sup></div><div role="paragraph">Teriflunomide, an oral disease-modifying therapy for relapsing multiple sclerosis, inhibits pyrimidine synthesis, reducing T-cell and B-cell activation.<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18 r19" id="body-ref-r19-1" href-manipulated="true">18,19</a></sup> According to the results of one comparative prospective trial<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4" id="body-ref-r4-2" href-manipulated="true" aria-label="Reference 4">4</a></sup> and a network meta-analysis,<sup><a href="#core-r20" role="doc-biblioref" data-xml-rid="r20" id="body-ref-r20" href-manipulated="true" aria-label="Reference 20">20</a></sup> the efficacy of teriflunomide to reduce annualized relapse rates is similar to that of interferons and glatiramer acetate, but according to observational studies<sup><a href="#core-r21" role="doc-biblioref" data-xml-rid="r21 r22" id="body-ref-r22" href-manipulated="true">21,22</a></sup> it is probably inferior to other oral and monoclonal antibody treatments for multiple sclerosis. We report the results of two phase 3, randomized, double-blind, double-dummy, active-controlled clinical trials of identical design, which assessed the efficacy and safety of subcutaneous ofatumumab as compared with oral teriflunomide.</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Trial Oversight</h3><div role="paragraph">The ASCLEPIOS I and II trials were designed by the sponsor (Novartis Pharma) in consultation with the steering committee. The investigators collected data, which were analyzed by the sponsor. The investigators, the sponsor, and the steering committee were unaware of treatment assignments throughout the trials. An independent data monitoring committee reviewed the safety of treatment using regular analyses performed by independent statisticians, who were not involved in the conduct of the trials. The manuscript was drafted with medical writing assistance funded by the sponsor. All the authors, including those employed by Novartis, had full access to the data and were involved in the critical review of all drafts of the manuscript. All the authors vouch for the accuracy and completeness of the data, the accurate reporting of adverse events, and the fidelity of the trials to the <a href="#ap1">protocols</a> (available with the full text of this article at NEJM.org). There were confidentiality agreements in place between the authors and the sponsor. Novartis supplied the trial drugs and placebo. The trials were conducted in accordance with the International Conference on Harmonisation guidelines for Good Clinical Practice<sup><a href="#core-r23" role="doc-biblioref" data-xml-rid="r23" id="body-ref-r23" href-manipulated="true" aria-label="Reference 23">23</a></sup> and the principles of the Declaration of Helsinki.<sup><a href="#core-r24" role="doc-biblioref" data-xml-rid="r24" id="body-ref-r24" href-manipulated="true" aria-label="Reference 24">24</a></sup> The protocol was approved by an institutional review board or ethics committee at each trial site. All the patients or their legal representatives provided written informed consent before commencing trial-related procedures.</div></section><section id="sec-1-2"><h3>Patients</h3><div role="paragraph">Eligibility criteria at screening included an age of 18 to 55 years; a diagnosis of multiple sclerosis (according to the 2010 revised McDonald criteria<sup><a href="#core-r25" role="doc-biblioref" data-xml-rid="r25" id="body-ref-r25" href-manipulated="true" aria-label="Reference 25">25</a></sup>) with a relapsing–remitting course or a secondary progressive course with disease activity (according to the criteria of Lublin et al.<sup><a href="#core-r26" role="doc-biblioref" data-xml-rid="r26" id="body-ref-r26" href-manipulated="true" aria-label="Reference 26">26</a></sup>); an Expanded Disability Status Scale (EDSS) score of 0 to 5.5 (scores range from 0 to 10.0, with higher scores indicating greater disability<sup><a href="#core-r27" role="doc-biblioref" data-xml-rid="r27" id="body-ref-r27" href-manipulated="true" aria-label="Reference 27">27</a></sup>); at least one relapse in the year before screening, at least two relapses in the 2 years before screening, or at least one lesion detected with the use of gadolinium enhancement (gadolinium-enhancing lesion) on magnetic resonance imaging (MRI) in the year before randomization; and a neurologically stable condition for at least 1 month before randomization. Key exclusion criteria, including the use of previous disease-modifying treatments and the durations of washout periods, are listed in the Additional Methodology Details section and Table S1 in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org.</div></section><section id="sec-1-3"><h3>Trial Design</h3><div role="paragraph">ASCLEPIOS I and II were randomized, double-blind, double-dummy, active-controlled, multicenter trials of identical design that were conducted concurrently. Patients, centers, and investigators could participate in only one of the trials. The trials featured a blinded sample-size reestimation to adjust the sample size and trial duration on the basis of a predefined overall minimum event rate. Each trial was powered for the primary end point (annualized relapse rate); the combined trials provided the required sample size and power for the preplanned meta-analysis of disability worsening confirmed at 3 months or 6 months. Eligible patients were randomly assigned in a 1:1 ratio through interactive response technology to receive ofatumumab at a dose of 20 mg subcutaneously every 4 weeks after 20-mg loading doses at days 1, 7, and 14 or oral teriflunomide at a dose of 14 mg once daily, for up to 30 months. Patients in the ofatumumab group also received oral placebo and patients in the teriflunomide group also received subcutaneous placebo corresponding to the active drug in the other group. Patients received their first subcutaneous injection at the trial site, which was administered by a health care provider (investigator, trial nurse, or trial coordinator). On days 7 and 14 and at month 1, patients returned to the site to administer the injection themselves under the supervision of trial staff, who provided training on the correct method. The patient’s ability to administer the injection had to be demonstrated and documented before administration at home after month 1 was permitted. Randomization was stratified according to geographic region and subtype of multiple sclerosis. (For more on trial design, see the Additional Methodology Details section in the <a href="#ap2">Supplementary Appendix</a>.)</div></section><section id="sec-1-4"><h3>End Points</h3><div role="paragraph">The primary end point was the annualized relapse rate up to the end of the trial. The annualized relapse rate was defined as the number of confirmed relapses of multiple sclerosis per year, according to prespecified criteria. Secondary clinical end points were disability worsening confirmed at 3 months, disability worsening confirmed at 6 months, and disability improvement (i.e., lessening of disability) confirmed at 6 months; a prespecified meta-analysis of these end points used the combined data from both trials. Secondary MRI end points included the number of gadolinium-enhancing lesions per T1-weighted MRI scan, the number of new or enlarging lesions on T2-weighted MRI per year, and the annual rate of brain-volume loss (see the protocols of the trials). A secondary biomarker end point was the serum neurofilament light chain concentration at month 3 and beyond, analyzed centrally by Navigate BioPharma using single-molecule-array immunoassay technology. Exploratory secondary end points included the relationship between neurofilament light chain concentration at baseline and the formation of new or enlarging lesions on T2-weighted MRI or brain-volume loss. Adverse events were recorded at all visits and graded according to the Common Terminology Criteria for Adverse Events (CTCAE).<sup><a href="#core-r28" role="doc-biblioref" data-xml-rid="r28" id="body-ref-r28" href-manipulated="true" aria-label="Reference 28">28</a></sup> (For more on trial end points, see the Additional Methodology Details section and Safety section in the <a href="#ap2">Supplementary Appendix</a>.)</div></section><section id="sec-1-5"><h3>Statistical Analysis</h3><div role="paragraph">We calculated that a sample size of 900 patients per trial would provide greater than 90% power in each trial to detect a 40% lower annualized relapse rate with ofatumumab than with teriflunomide. In the combined data from both trials, a sample of 900 patients per trial (i.e. a total of 1800 patients) would provide 90% power and 80% power to detect a 38.6% lower risk of disability worsening confirmed at 3 months and at 6 months, respectively, with ofatumumab than with teriflunomide. Sample size could be increased to a maximum of 1250 patients per trial, and the end of the trials was declared on the basis of a statistical projection when sufficient events had accumulated to power the analysis for the primary end point and the two end points of disability worsening. (For details, see the statistical analysis plan, available with the <a href="#ap1">protocols</a> at NEJM.org, and the Statistical Analyses section in the <a href="#ap2">Supplementary Appendix</a>.)</div><div role="paragraph">Efficacy analyses were carried out according to the intention-to-treat principle. Data on the annualized relapse rate were analyzed with the use of a negative binomial-regression model, with an offset for time spent in the trial in years to adjust for varying treatment durations among patients. The type I error was controlled by a statistical testing procedure, with seven prespecified secondary end points tested; disability worsening confirmed at 3 months or 6 months and disability improvement confirmed at 6 months were tested in preplanned meta-analyses of the combined trials only if the primary null hypothesis for the annualized relapse rate was rejected in both trials independently. Other secondary end points were tested in hierarchical sequential order in each trial (number of gadolinium-enhancing lesions per T1-weighted MRI scan, annualized rate of new or enlarging lesions on T2-weighted MRI, serum neurofilament light chain concentration, and annual rate of brain-volume loss) as long as all preceding null hypotheses could be rejected (Fig. S1).</div><div role="paragraph">Data from disability-related end points were analyzed with the use of a Cox proportional-hazards model, stratified according to trial. Numbers of gadolinium-enhancing lesions on T1-weighted MRI and new or enlarging lesions on T2-weighted MRI were assessed with the use of negative binomial-regression models; for analysis of data on gadolinium-enhancing lesions on T1-weighted MRI, the number of available MRI scans was used as an offset; for lesions on T2-weighted MRI, the time between the last available scan and baseline scan was used as an offset.</div><div role="paragraph">Data on serum neurofilament light chain concentration were analyzed with the use of a repeated-measures model after log transformation of the data; the treatment effect is reported as a percentage reduction in neurofilament light chain concentration on the basis of the ratio of geometric means (relative reduction in geometric means with ofatumumab vs. teriflunomide). The annual rate of brain-volume loss was estimated as the marginal slope estimate from a random-coefficient model with random intercept and slope on the basis of assessments of the percentage change from baseline in brain volume performed at month 12, month 24, and at the end of the trial. The primary end point and key secondary end points used analysis methods that handle missing data under missing-at-random assumptions. Empirical evidence for data missing at random is presented in Table S2 and Figures S2 and S3, together with sensitivity analyses under missing-not-at-random assumptions for the primary and key secondary disability-related end points (Tables S3 and S4).</div><div role="paragraph">The safety population included all the patients who received trial drugs. Safety data were collected during the treatment period (screening to end of trial) and the safety follow-up period until a patient’s last visit. After the last dose of trial drug, patients were followed for at least 9 months. Adverse events that occurred during the treatment period were reported from the first dose and up to 100 days (approximately 5 times the half-life of ofatumumab) after permanent trial-drug discontinuation, and all serious adverse events that were reported up to the last visit by the last patient were analyzed. Safety end points are reported for the individual and combined trials.</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Patients</h3><div role="paragraph">From October 2016 through March 2018, a total of 1882 patients were enrolled at 385 sites in 37 countries: 927 in ASCLEPIOS I (465 assigned to ofatumumab and 462 to teriflunomide) and 955 in ASCLEPIOS II (481 assigned to ofatumumab and 474 to teriflunomide). The median time in trial was 1.6 years (1.5 years in ASCLEPIOS I and 1.6 years in ASCLEPIOS II). More than 30% of the patients had a time in trial longer than 2 years (Table S2). Individual times in trial and times to trial-drug discontinuation and trial discontinuation are presented in Figures S2 and S3. The demographic and disease characteristics of the patients at baseline were similar in the two trials and in the treatment groups (<a href="#t1">Table 1</a>). In ASCLEPIOS I, the trial was completed by 89.5% of the patients in the ofatumumab group and by 81.4% of those in the teriflunomide group. In ASCLEPIOS II, the corresponding percentages were 82.5% and 82.1%. Screening, randomization, and follow-up are summarized in Figure S4.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1917246_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1917246_t1.jpg"><img src="/cms/10.1056/NEJMoa1917246/asset/46cf2105-2e46-4832-a4e5-c4e358c5a928/assets/images/large/nejmoa1917246_t1.jpg" height="2750" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders" colspan="2"><span>ASCLEPIOS I Trial</span></th><th class="txxr-borders" colspan="2"><span>ASCLEPIOS II Trial</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Ofatumumab<br>(N=465)</th><th class="xxxx-borders">Teriflunomide<br>(N=462)</th><th class="xxxx-borders">Ofatumumab<br>(N=481)</th><th class="xxxr-borders">Teriflunomide<br>(N=474)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Age — yr<a href="#t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">38.9±8.8</td><td class="xxxx-borders shading">37.8±9.0</td><td class="xxxx-borders shading">38.0±9.3</td><td class="xxxr-borders shading">38.2±9.5</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Female sex — no. (%)</td><td class="xxxx-borders">318 (68.4)</td><td class="xxxx-borders">317 (68.6)</td><td class="xxxx-borders">319 (66.3)</td><td class="xxxr-borders">319 (67.3)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Type of multiple sclerosis — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Relapsing–remitting</td><td class="xxxx-borders">438 (94.2)</td><td class="xxxx-borders">434 (93.9)</td><td class="xxxx-borders">452 (94.0)</td><td class="xxxr-borders">450 (94.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Secondary progressive</td><td class="xxxx-borders shading">27 (5.8)</td><td class="xxxx-borders shading">28 (6.1)</td><td class="xxxx-borders shading">29 (6.0)</td><td class="xxxr-borders shading">24 (5.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Time since symptom onset — yr</td><td class="xxxx-borders">8.36±6.84</td><td class="xxxx-borders">8.18±7.21</td><td class="xxxx-borders">8.20±7.40</td><td class="xxxr-borders">8.19±7.38</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Time since diagnosis — yr</td><td class="xxxx-borders shading">5.77±6.05</td><td class="xxxx-borders shading">5.64±6.20</td><td class="xxxx-borders shading">5.59±6.38</td><td class="xxxr-borders shading">5.48±6.00</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">No previous disease-modifying therapy — no. (%)</td><td class="xxxx-borders">191 (41.1)</td><td class="xxxx-borders">182 (39.4)</td><td class="xxxx-borders">195 (40.5)</td><td class="xxxr-borders">181 (38.2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Previous disease-modifying therapy — no. (%)<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Any interferon beta</td><td class="xxxx-borders">189 (40.6)</td><td class="xxxx-borders">193 (41.8)</td><td class="xxxx-borders">197 (41.0)</td><td class="xxxr-borders">193 (40.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Glatiramer acetate</td><td class="xxxx-borders shading">124 (26.7)</td><td class="xxxx-borders shading">106 (22.9)</td><td class="xxxx-borders shading">118 (24.5)</td><td class="xxxr-borders shading">149 (31.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Dimethyl fumarate</td><td class="xxxx-borders">36 (7.7)</td><td class="xxxx-borders">37 (8.0)</td><td class="xxxx-borders">36 (7.5)</td><td class="xxxr-borders">44 (9.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Teriflunomide</td><td class="xxxx-borders shading">8 (1.7)</td><td class="xxxx-borders shading">6 (1.3)</td><td class="xxxx-borders shading">13 (2.7)</td><td class="xxxr-borders shading">9 (1.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Daclizumab</td><td class="xxxx-borders">5 (1.1)</td><td class="xxxx-borders">12 (2.6)</td><td class="xxxx-borders">8 (1.7)</td><td class="xxxr-borders">7 (1.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Fingolimod</td><td class="xxxx-borders shading">10 (2.2)</td><td class="xxxx-borders shading">15 (3.2)</td><td class="xxxx-borders shading">13 (2.7)</td><td class="xxxr-borders shading">10 (2.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Natalizumab</td><td class="xxxx-borders">31 (6.7)</td><td class="xxxx-borders">36 (7.8)</td><td class="xxxx-borders">26 (5.4)</td><td class="xxxr-borders">20 (4.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Any B-cell therapy<a href="#t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">2 (0.4)</td><td class="xxxx-borders shading">3 (0.6)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Laquinimod</td><td class="xxxx-borders">5 (1.1)</td><td class="xxxx-borders">4 (0.9)</td><td class="xxxx-borders">2 (0.4)</td><td class="xxxr-borders">7 (1.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Other disease-modifying therapy<a href="#t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">52 (11.2)</td><td class="xxxx-borders shading">65 (14.1)</td><td class="xxxx-borders shading">68 (14.1)</td><td class="xxxr-borders shading">81 (17.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">No. of relapses in previous 12 mo</td><td class="xxxx-borders">1.2±0.6</td><td class="xxxx-borders">1.3±0.7</td><td class="xxxx-borders">1.3±0.7</td><td class="xxxr-borders">1.3±0.7</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">No. of relapses in previous &gt;12–24 mo</td><td class="xxxx-borders shading">0.9±0.9</td><td class="xxxx-borders shading">0.9±1.2</td><td class="xxxx-borders shading">0.7±0.9</td><td class="xxxr-borders shading">0.8±1.0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">EDSS score<a href="#t1fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders">2.97±1.36</td><td class="xxxx-borders">2.94±1.36</td><td class="xxxx-borders">2.90±1.34</td><td class="xxxr-borders">2.86±1.37</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">No. of gadolinium-enhancing lesions per T1-weighted MRI scan</td><td class="xxxx-borders shading">1.7±4.9</td><td class="xxxx-borders shading">1.2±2.6</td><td class="xxxx-borders shading">1.6±4.1</td><td class="xxxr-borders shading">1.5±4.1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Absence of gadolinium-enhancing lesions on T1-weighted MRI — no. (%)</td><td class="xxxx-borders">291 (62.6)</td><td class="xxxx-borders">293 (63.4)</td><td class="xxxx-borders">270 (56.1)</td><td class="xxxr-borders">291 (61.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Volume of lesions on T2-weighted MRI — cm<sup>3</sup></td><td class="xxxx-borders shading">13.2±13.3</td><td class="xxxx-borders shading">13.1±14.6</td><td class="xxxx-borders shading">14.3±14.2</td><td class="xxxr-borders shading">12.0±13.0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Neurofilament light chain concentration — pg/ml</td><td class="xxxx-borders">13.3±13.2</td><td class="xxxx-borders">11.7±9.3</td><td class="xxxx-borders">14.7±18.2</td><td class="xxxr-borders">13.4±14.0</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02 shading" data-xml-align="left">Normalized brain volume — cm<sup>3</sup></td><td class="xbxx-borders shading">1439±81</td><td class="xbxx-borders shading">1442±79</td><td class="xbxx-borders shading">1441±77</td><td class="xbxr-borders shading">1446±77</td></tr></tbody></table></div><figcaption><div class="caption">Demographic and Disease Characteristics of the Patients at Baseline (Full Analysis Set).<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">Plus–minus values are means ±SD. Data on time since symptom onset were missing for 1 patient in the teriflunomide group in the ASCLEPIOS II trial. Data on the number of relapses in the previous more than 12 to 24 months were missing for 1 patient in each group in the ASCLEPIOS II trial. Data on the Expanded Disability Status Scale (EDSS) score were missing for 1 patient in the teriflunomide group in each trial. Data on the number of gadolinium-enhancing lesions per T1-weighted magnetic resonance imaging (MRI) scan were missing for 11 patients in the ofatumumab group and for 10 in the teriflunomide group in the ASCLEPIOS I trial and for 12 in the ofatumumab group and 4 in the teriflunomide group in the ASCLEPIOS II trial. Data on the volume of lesions on T2-weighted MRI were missing for 4 patients in the ofatumumab group and for 5 in the teriflunomide group in the ASCLEPIOS I trial and for 8 in the ofatumumab group and 1 in the teriflunomide group in the ASCLEPIOS II trial. Data on neurofilament light chain concentration were missing for 18 patients in the ofatumumab group and for 41 in the teriflunomide group in the ASCLEPIOS I trial and for 35 in the ofatumumab group and 42 in the teriflunomide group in the ASCLEPIOS II trial. Data on normalized brain volume were missing for 5 patients in the ofatumumab group and for 8 in the teriflunomide group in the ASCLEPIOS I trial and for 12 in the ofatumumab group and 1 in the teriflunomide group in the ASCLEPIOS II trial.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">Age at baseline was calculated from the date of the first administration of trial drug and the birth year (no exact birth date was captured for reasons of data privacy). Eligibility for trial entry was assessed at the screening visit.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t1fn3" role="paragraph">A patient could be counted in multiple categories.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t1fn4" role="paragraph">In the ASCLEPIOS I trial, rituximab had been received by 1 patient in the teriflunomide group, and ocrelizumab had been received by 2 patients in the ofatumumab group and by 2 in the teriflunomide group.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t1fn5" role="paragraph">This category includes all medications that were recorded by the investigator as a disease-modifying therapy but were not included in the listed medications.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="t1fn6" role="paragraph">Scores on the Expanded Disability Status Scale (EDSS) range from 0 to 10.0, with higher scores indicating worse disability. The score at baseline was defined as the score at the last assessment before the first dose administration of trial drug. Eligibility was assessed at the screening visit.</div></div></div></figcaption></figure></div></section><section id="sec-2-2"><h3>Efficacy</h3><section id="sec-2-2-1"><h4>Primary End Point</h4><div role="paragraph">In ASCLEPIOS I, the adjusted annualized relapse rate was 0.11 with ofatumumab and 0.22 with teriflunomide (difference, −0.11; 95% confidence interval [CI], −0.16 to −0.06; P&lt;0.001). The corresponding rates in ASCLEPIOS II were 0.10 and 0.25 (difference, −0.15; 95% CI, −0.20 to −0.09; P&lt;0.001) (<a href="#t2">Table 2</a>).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1917246_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1917246_t2.jpg"><img src="/cms/10.1056/NEJMoa1917246/asset/c66c4b2b-55db-48e2-8435-2a3436f6b4be/assets/images/large/nejmoa1917246_t2.jpg" height="3314" width="2615" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">End Point</th><th class="txxx-borders" colspan="3"><span>ASCLEPIOS I Trial</span></th><th class="txxx-borders" colspan="3"><span>ASCLEPIOS II Trial</span></th><th class="txxr-borders" colspan="3"><span>Pooled Trials</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Ofatumumab<br>(N=465)</th><th class="xxxx-borders">Teriflunomide<br>(N=462)</th><th class="xxxx-borders">P<br>Value</th><th class="xxxx-borders">Ofatumumab<br>(N=481)</th><th class="xxxx-borders">Teriflunomide<br>(N=474)</th><th class="xxxx-borders">P<br>Value</th><th class="xxxx-borders">Ofatumumab<br>(N=946)</th><th class="xxxx-borders">Teriflunomide<br>(N=936)</th><th class="xxxr-borders">P<br>Value</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Primary end point</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Total no. of relapses</td><td class="xxxx-borders">90</td><td class="xxxx-borders">177</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">95</td><td class="xxxx-borders">198</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">No. of patients evaluated</td><td class="xxxx-borders shading">454</td><td class="xxxx-borders shading">452</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">469</td><td class="xxxx-borders shading">469</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Adjusted annualized relapse rate (95% CI)</td><td class="xxxx-borders">0.11<br>(0.09 to 0.14)</td><td class="xxxx-borders">0.22<br>(0.18 to 0.26)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">0.10<br>(0.08 to 0.13)</td><td class="xxxx-borders">0.25<br>(0.21 to 0.30)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Difference (95% CI)</td><td class="xxxx-borders shading" colspan="2">−0.11 (−0.16 to −0.06)</td><td class="xxxx-borders shading">&lt;0.001</td><td class="xxxx-borders shading" colspan="2">−0.15 (−0.20 to −0.09)</td><td class="xxxx-borders shading">&lt;0.001</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Rate ratio (95% CI)</td><td class="xxxx-borders" colspan="2">0.49 (0.37 to 0.65)</td><td class="xxxx-borders">&lt;0.001</td><td class="xxxx-borders" colspan="2">0.42 (0.31 to 0.56)</td><td class="xxxx-borders">&lt;0.001</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Disability-related end points</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Disability worsening confirmed at 3 mo</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">No. of events during the trial/no. of patients</td><td class="xxxx-borders shading">45/465</td><td class="xxxx-borders shading">63/459</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">43/479</td><td class="xxxx-borders shading">62/472</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">88/944</td><td class="xxxx-borders shading">125/931</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Kaplan–Meier estimate at 24 mo — %</td><td class="xxxx-borders">11.3</td><td class="xxxx-borders">15.4</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">10.5</td><td class="xxxx-borders">14.6</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">10.9</td><td class="xxxx-borders">15.0</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Hazard ratio (95% CI)</td><td class="xxxx-borders shading" colspan="2">0.65 (0.45 to 0.96)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading" colspan="2">0.66 (0.45 to 0.97)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading" colspan="2">0.66 (0.50 to 0.86)</td><td class="xxxr-borders shading">0.002</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Disability worsening confirmed at 6 mo</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">No. of events during the trial/no. of patients</td><td class="xxxx-borders shading">35/465</td><td class="xxxx-borders shading">53/459</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">36/479</td><td class="xxxx-borders shading">46/472</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">71/944</td><td class="xxxx-borders shading">99/931</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Kaplan–Meier estimate at 24 mo — %</td><td class="xxxx-borders">8.2</td><td class="xxxx-borders">13.0</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">8.0</td><td class="xxxx-borders">10.9</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">8.1</td><td class="xxxx-borders">12.0</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Hazard ratio (95% CI)</td><td class="xxxx-borders shading" colspan="2">0.61 (0.40 to 0.93)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading" colspan="2">0.76 (0.49 to 1.17)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading" colspan="2">0.68 (0.50 to 0.92)</td><td class="xxxr-borders shading">0.01</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Disability improvement confirmed at 6 mo</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">No. of events during the trial/no. of patients</td><td class="xxxx-borders shading">33/375</td><td class="xxxx-borders shading">26/363</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">41/374</td><td class="xxxx-borders shading">27/360</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">74/749</td><td class="xxxx-borders shading">53/723</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Kaplan–Meier estimate at 24 mo — %</td><td class="xxxx-borders">9.7</td><td class="xxxx-borders">8.2</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">12.3</td><td class="xxxx-borders">8.1</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">11.0</td><td class="xxxx-borders">8.1</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Hazard ratio (95% CI)</td><td class="xxxx-borders shading" colspan="2">1.19 (0.71 to 1.98)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading" colspan="2">1.52 (0.93 to 2.47)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading" colspan="2">1.35 (0.95 to 1.92)</td><td class="xxxr-borders shading">0.09</td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><b>MRI-related end points</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Gd+ lesions on T1-weighted MRI</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">No. of patients evaluated</td><td class="xxxx-borders">432</td><td class="xxxx-borders">422</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">439</td><td class="xxxx-borders">434</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Mean no. of lesions per scan (95% CI)</td><td class="xxxx-borders shading">0.01<br>(0.01 to 0.02)</td><td class="xxxx-borders shading">0.45<br>(0.36 to 0.58)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0.03<br>(0.02 to 0.05)</td><td class="xxxx-borders shading">0.51<br>(0.40 to 0.66)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Rate ratio (95% CI)</td><td class="xxxx-borders" colspan="2">0.03 (0.01 to 0.05)</td><td class="xxxx-borders">&lt;0.001</td><td class="xxxx-borders" colspan="2">0.06 (0.04 to 0.10)</td><td class="xxxx-borders">&lt;0.001</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">New or enlarging lesions on T2-weighted MRI by end of trial</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">No. of patients evaluated</td><td class="xxxx-borders">440</td><td class="xxxx-borders">431</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">448</td><td class="xxxx-borders">443</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Mean no. of lesions per yr (95% CI)</td><td class="xxxx-borders shading">0.72<br>(0.61 to 0.85)</td><td class="xxxx-borders shading">4.00<br>(3.47 to 4.61)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0.64<br>(0.55 to 0.75)</td><td class="xxxx-borders shading">4.15<br>(3.64 to 4.74)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Rate ratio (95% CI)</td><td class="xxxx-borders" colspan="2">0.18 (0.15 to 0.22)</td><td class="xxxx-borders">&lt;0.001</td><td class="xxxx-borders" colspan="2">0.15 (0.13 to 0.19)</td><td class="xxxx-borders">&lt;0.001</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlr-borders hanging02 shading" colspan="10">Brain-volume change</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">No. of patients evaluated</td><td class="xxxx-borders">418</td><td class="xxxx-borders">409</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">437</td><td class="xxxx-borders">434</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Annual rate of change (95% CI) — %<a href="#t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">−0.28<br>(−0.34 to −0.22)</td><td class="xxxx-borders shading">−0.35<br>(−0.41 to −0.29)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">−0.29<br>(−0.35 to −0.23)</td><td class="xxxx-borders shading">−0.35<br>(−0.42 to −0.29)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Difference (95% CI) — percentage points</td><td class="xxxx-borders" colspan="2">0.07 (−0.02 to 0.15)</td><td class="xxxx-borders">0.12</td><td class="xxxx-borders" colspan="2">0.07 (−0.02 to 0.15)</td><td class="xxxx-borders">0.13</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Serum NfL concentration</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">At 3 mo</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">No. of patients evaluated</td><td class="xxxx-borders shading">430</td><td class="xxxx-borders shading">404</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">425</td><td class="xxxx-borders shading">423</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Geometric mean (95% CI) — pg/ml</td><td class="xxxx-borders">8.8<br>(8.5 to 9.1)</td><td class="xxxx-borders">9.4<br>(9.1 to 9.8)</td><td class="xxxx-borders">0.01</td><td class="xxxx-borders">8.9<br>(8.6 to 9.2)</td><td class="xxxx-borders">10.0<br>(9.7 to 10.4)</td><td class="xxxx-borders">&lt;0.001</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">At 12 mo</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">No. of patients evaluated</td><td class="xxxx-borders">414</td><td class="xxxx-borders">399</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">406</td><td class="xxxx-borders">406</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Geometric mean (95% CI) — pg/ml</td><td class="xxxx-borders shading">7.0<br>(6.7 to 7.3)</td><td class="xxxx-borders shading">9.6<br>(9.2 to 10.1)</td><td class="xxxx-borders shading">&lt;0.001</td><td class="xxxx-borders shading">7.1<br>(6.8 to 7.4)</td><td class="xxxx-borders shading">9.5<br>(9.1 to 10.0)</td><td class="xxxx-borders shading">&lt;0.001</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">At 24 mo</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">No. of patients evaluated</td><td class="xxxx-borders shading">371</td><td class="xxxx-borders shading">350</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">345</td><td class="xxxx-borders shading">349</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left">Geometric mean (95% CI) — pg/ml</td><td class="xbxx-borders">6.9<br>(6.6 to 7.2)</td><td class="xbxx-borders">9.0<br>(8.6 to 9.5)</td><td class="xbxx-borders">&lt;0.001</td><td class="xbxx-borders">6.8<br>(6.5 to 7.1)</td><td class="xbxx-borders">9.0<br>(8.6 to 9.4)</td><td class="xbxx-borders">&lt;0.001</td><td class="xbxx-borders">&nbsp;</td><td class="xbxx-borders">&nbsp;</td><td class="xbxr-borders">&nbsp;</td></tr></tbody></table></div><figcaption><div class="caption">Clinical, MRI, and Biomarker End Points (Full Analysis Set).<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">All difference values, rate ratios, and hazard ratios are for ofatumumab compared with teriflunomide. Gd+ denotes gadolinium enhancing, and NfL neurofilament light chain.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t2fn2" role="paragraph">The annual rate of brain-volume change was estimated according to the slope from a random-coefficient model, on the basis of assessment of the percentage change from baseline in brain volume performed at month 12, month 24, and the end of the trial.</div></div></div></figcaption></figure></div></section><section id="sec-2-2-2"><h4>Disability-Related End Points</h4><div role="paragraph">In the meta-analysis of both trials, the percentage of patients (Kaplan–Meier estimate at month 24) with disability worsening confirmed at 3 months was 10.9% with ofatumumab and 15.0% with teriflunomide (hazard ratio, 0.66; 95% CI, 0.50 to 0.86; P=0.002) (<a href="#f1">Figure 1A</a> and <a href="#t2">Table 2</a>). The percentage of patients with disability worsening confirmed at 6 months was 8.1% with ofatumumab and 12.0% with teriflunomide (hazard ratio, 0.68; 95% CI, 0.50 to 0.92; P=0.01) (<a href="#f1">Figure 1B</a> and <a href="#t2">Table 2</a>). Corresponding percentages of patients with disability improvement confirmed at 6 months from both trials were 11.0% with ofatumumab and 8.1% with teriflunomide (hazard ratio, 1.35; 95% CI, 0.95 to 1.92; P=0.09) (<a href="#f1">Figure 1C</a> and <a href="#t2">Table 2</a>). The effect of ofatumumab on confirmed disability worsening was consistent across the two trials, as was the absence of a significant between-group difference in confirmed disability improvement (<a href="#t2">Table 2</a>).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1917246_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1917246_f1.jpg"><img src="/cms/10.1056/NEJMoa1917246/asset/fb4af6fb-f4bc-4618-856f-84a6dc6f5677/assets/images/large/nejmoa1917246_f1.jpg" height="3438" width="2276" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Confirmed Disability Worsening and Improvement.</div><div class="notes"><div role="doc-footnote">Shown are Kaplan–Meier estimates of the percentages of patients with disability worsening confirmed at 3 months (Panel A) and at 6 months (Panel B) and of patients with disability improvement (i.e., lessening of disability) confirmed at 6 months (Panel C) in time-to-event analyses in the combined trial populations. Disability worsening confirmed at 3 months or 6 months was defined as an increase from baseline in the Expanded Disability Status Scale (EDSS) score (on a scale from 0 to 10.0, with higher scores indicating worse disability) that was sustained for at least 3 or 6 months. For patients with a baseline EDSS score of 0, an increase in the EDSS score of at least 1.5 points was required; for patients with a baseline EDSS score of 1.0 to 5.0, the criterion was an increase of at least 1.0 point; and for patients with a baseline EDSS score of at least 5.5 points, the criterion was an increase of at least 0.5 points. Disability improvement confirmed at 6 months was defined as a decrease from baseline in the EDSS score that was sustained for at least 6 months. For patients with baseline EDSS scores of 2.0 to 6.0 points, a decrease of at least 1.0 point was required; for patients with baseline EDSS scores of 6.5 to 9.0 points, a decrease of at least 0.5 points was required. The numbers shown on the curves represent Kaplan–Meier estimates of the risk of the event at 24 months (marked by the vertical dashed line). The insets show the same data on an expanded y axis.</div></div></figcaption></figure></div></section><section id="sec-2-2-3"><h4>MRI-Related End Points</h4><div role="paragraph">In ASCLEPIOS I, the mean number of gadolinium-enhancing lesions per T1-weighted MRI scan was 0.01 with ofatumumab and 0.45 with teriflunomide (97% lower number of lesions with ofatumumab, P&lt;0.001); in ASCLEPIOS II, the corresponding numbers were 0.03 and 0.51, respectively (94% lower with ofatumumab, P&lt;0.001) (<a href="#t2">Table 2</a>). In ASCLEPIOS I, the mean number of new or enlarging lesions per year on T2-weighted MRI was 0.72 with ofatumumab and 4.00 with teriflunomide (82% lower number of lesions with ofatumumab, P&lt;0.001); corresponding values in ASCLEPIOS II were 0.64 and 4.15, respectively (85% lower with ofatumumab, P&lt;0.001) (<a href="#t2">Table 2</a> and Table S5). The annual rate of brain-volume loss did not differ significantly between the ofatumumab group and the teriflunomide group (−0.28% with ofatumumab and −0.35% with teriflunomide in ASCLEPIOS I and −0.29% with ofatumumab and −0.35% with teriflunomide in ASCLEPIOS II) (<a href="#t2">Table 2</a> and Fig. S5).</div></section><section id="sec-2-2-4"><h4>Serum Neurofilament Light Chain Concentration</h4><div role="paragraph">In ASCLEPIOS I, the serum neurofilament light chain concentration was lower in the ofatumumab group than in the teriflunomide group by 7% at month 3 (P=0.01), by 27% at month 12, and by 23% at month 24. Corresponding differences in ASCLEPIOS II were 11% (P&lt;0.001), 26%, and 24% (<a href="#t2">Table 2</a> and Fig. S6). Adjusted annualized mean rates of new or enlarging lesions on T2-weighted MRI according to quartiles of neurofilament light chain concentration at baseline are presented in Table S6 and Figure S7.</div></section></section><section id="sec-2-3"><h3>Safety</h3><section id="sec-2-3-1"><h4>Adverse Events</h4><div role="paragraph">Adverse events up to 100 days after the last administration of a trial drug, serious adverse events up to the last visit by the last patient, adverse events leading to treatment discontinuation, and deaths are summarized in <a href="#t3">Table 3</a>. In the combined analyses, 791 of 946 patients (83.6%) in the ofatumumab group reported an adverse event, as compared with 788 of 936 patients (84.2%) in the teriflunomide group. Adverse events that occurred in at least 10% of the patients treated with ofatumumab were injection-related reactions, nasopharyngitis, headache, injection-site reaction, upper respiratory tract infection, and urinary tract infection; events that occurred in at least 10% of those treated with teriflunomide were nasopharyngitis, injection-related reactions, alopecia, upper respiratory tract infection, headache, and diarrhea (Table S7). Serious adverse events were reported in 9.1% of the patients treated with ofatumumab and 7.9% of those treated with teriflunomide. One death occurred in the teriflunomide group (aortic dissection) during the post-treatment follow-up period.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 3</div><nav><a href="#t3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1917246_t3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t3" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1917246_t3.jpg"><img src="/cms/10.1056/NEJMoa1917246/asset/73e332d2-7649-483e-8c12-8b09e8140168/assets/images/large/nejmoa1917246_t3.jpg" height="1751" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Variable</th><th class="txxx-borders" colspan="2"><span>ASCLEPIOS I Trial</span></th><th class="txxr-borders" colspan="2"><span>ASCLEPIOS II Trial</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Ofatumumab<br>(N=465)</th><th class="xxxx-borders">Teriflunomide<br>(N=462)</th><th class="xxxx-borders">Ofatumumab<br>(N=481)</th><th class="xxxr-borders">Teriflunomide<br>(N=474)</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="4"><span>number of patients (percent)</span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Any adverse event</td><td class="xxxx-borders shading">382 (82.2)</td><td class="xxxx-borders shading">380 (82.3)</td><td class="xxxx-borders shading">409 (85.0)</td><td class="xxxr-borders shading">408 (86.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Adverse event leading to treatment discontinuation</td><td class="xxxx-borders">27 (5.8)</td><td class="xxxx-borders">24 (5.2)</td><td class="xxxx-borders">27 (5.6)</td><td class="xxxr-borders">25 (5.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Infection</td><td class="xxxx-borders shading">229 (49.2)</td><td class="xxxx-borders shading">238 (51.5)</td><td class="xxxx-borders shading">259 (53.8)</td><td class="xxxr-borders shading">255 (53.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Injection-related systemic reaction<a href="#t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">75 (16.1)</td><td class="xxxx-borders">76 (16.5)</td><td class="xxxx-borders">116 (24.1)</td><td class="xxxr-borders">64 (13.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Serious adverse event</td><td class="xxxx-borders shading">48 (10.3)</td><td class="xxxx-borders shading">38 (8.2)</td><td class="xxxx-borders shading">38 (7.9)</td><td class="xxxr-borders shading">36 (7.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Serious infection<a href="#t3fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">12 (2.6)</td><td class="xxxx-borders">7 (1.5)</td><td class="xxxx-borders">12 (2.5)</td><td class="xxxr-borders">10 (2.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Serious injection-related reaction</td><td class="xxxx-borders shading">2 (0.4)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Neoplasm<a href="#t3fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">3 (0.6)</td><td class="xxxx-borders">3 (0.6)</td><td class="xxxx-borders">2 (0.4)</td><td class="xxxr-borders">1 (0.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02 shading" data-xml-align="left">Death</td><td class="xbxx-borders shading">0</td><td class="xbxx-borders shading">0</td><td class="xbxx-borders shading">0</td><td class="xbxr-borders shading">1 (0.2)<a href="#t3fn5" role="doc-noteref">¶</a></td></tr></tbody></table></div><figcaption><div class="caption">Adverse Events (Safety Population).<a href="#t3fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t3fn1" role="paragraph">Shown is the number of patients with at least one event and the percentage of all patients in each group. Adverse events were coded according to the preferred terms in the <i>Medical Dictionary for Regulatory Activities</i>, version 20.0. Relapses of multiple sclerosis that were reported as adverse events were excluded.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t3fn2" role="paragraph">Only reactions or symptoms that occurred within 24 hours after injection are included (i.e., time to onset of reaction, ≤24 hours).</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t3fn3" role="paragraph">Serious infections and infestations that were reported in the ofatumumab group were appendicitis (in 8 patients), gastroenteritis (in 3), urinary tract infection (in 3), influenza (in 2), and cystitis, escherichia urinary tract infection, kidney infection, lower respiratory tract infection, neutropenic sepsis, osteomyelitis, pneumonia, upper respiratory tract infection, urosepsis, and viral respiratory tract infection (in 1 patient each). Serious infections and infestations that were reported in the teriflunomide group were appendicitis (in 2 patients), urinary tract infection (in 2), and abscess of the sweat glands, campylobacter infection, cystitis, influenza pneumonia, osteomyelitis, paronychia, peritonitis, pneumonia, postoperative abscess, salpingo-oophoritis, sepsis, tickborne viral encephalitis, and viral infection (in 1 patient each).</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t3fn4" role="paragraph">Neoplasms that were reported in patients receiving ofatumumab were one case of malignant melanoma in situ (time to onset, 39 days), one case of invasive breast carcinoma (time to onset, 149 days), one case of recurrent non-Hodgkin’s lymphoma (time to onset, 31 days), and two cases of basal-cell carcinoma (time to onset, 120 and 258 days). Neoplasms that were reported in patients receiving teriflunomide were one case of fibrosarcoma (time to onset, 652 days), one case of cervix carcinoma (time to onset, 341 days), and two cases of basal-cell carcinoma (time to onset, 8 and 401 days). None of the malignant events were considered by the investigator to be related to trial treatment, and no cluster of neoplasms was identified.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t3fn5" role="paragraph">The cause of death was aortic dissection.</div></div></div></figcaption></figure></div></section><section id="sec-2-3-2"><h4>Infections</h4><div role="paragraph">Infections and infestations were reported in 488 patients (51.6%) who received ofatumumab and 493 (52.7%) who received teriflunomide. Infections reported in 10% or more of the patients in either group across both trials were nasopharyngitis (18.0% with ofatumumab and 16.7% with teriflunomide), upper respiratory tract infection (10.3% and 12.8%, respectively), and urinary tract infection (10.3% and 8.3%, respectively). The percentage of patients who reported a serious infection was 2.5% with ofatumumab and 1.8% with teriflunomide. The percentage of patients who reported a herpesvirus-associated infection was 4.9% in the ofatumumab group and 4.2% in the teriflunomide group. All herpesvirus-associated infections were mild (CTCAE grade 1) or moderate (grade 2), resolved while patients continued therapy, and did not lead to treatment discontinuation. Bronchitis was reported in 2.5% of the patients treated with ofatumumab and in 3.5% of those treated with teriflunomide; corresponding percentages for pneumonia were 0.3% and 0.7%, respectively. Appendicitis was reported in 8 patients who received ofatumumab and in 2 who received teriflunomide. No opportunistic infections were reported (Table S7).</div></section><section id="sec-2-3-3"><h4>Injection-Related Reactions</h4><div role="paragraph">At least one injection-related systemic reaction, defined as systemic reactions occurring within 24 hours after injection (see the list of symptoms in the Safety section in the <a href="#ap2">Supplementary Appendix</a>), was reported in 20.2% of the patients who received ofatumumab and in 15.0% of those given placebo injections in the teriflunomide group (for details on injection-related premedication, see Tables S8 and S9). Injection-site reactions occurred in 10.9% and 5.6% of patients who received ofatumumab or placebo injections, respectively. Most injection-related systemic reactions (e.g., headache, flushing, and “other”) occurred at the first injection (14.4% and 7.5% among the patients who received ofatumumab or placebo-dummy injections, respectively) (Fig. S8), were mild or moderate (grades 1 or 2), and were managed without treatment. Two severe (grade 3) injection-related systemic reactions were reported in the ofatumumab group (0.2%), one of which led to drug discontinuation after the first injection (0.1%). No life-threatening or anaphylactoid injection-related reactions (grade 4) were reported. After the fourth injection, 74.4% of patients administered ofatumumab at home.</div></section><section id="sec-2-3-4"><h4>Other Safety Findings</h4><div role="paragraph">Five neoplasms (0.5%) occurred in the ofatumumab group (two cases of basal-cell carcinoma and one case each of malignant melanoma in situ, recurrent non-Hodgkin’s lymphoma, and invasive breast carcinoma) and four (0.4%) in the teriflunomide group (two cases of basal-cell carcinoma and one case each of cervix carcinoma and fibrosarcoma) (<a href="#t3">Table 3</a>). Findings regarding B-cell depletion and antidrug-binding antibodies are reported in Figures S9 through S11.</div></section></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">In these two simultaneously conducted active-controlled trials involving patients with relapsing multiple sclerosis, both ofatumumab and teriflunomide were associated with low relapse rates. The relapse rate was significantly lower with ofatumumab than with teriflunomide in each of the two trials. In a prespecified meta-analysis of both trials, the percentages of patients with disability worsening confirmed at 3 months or 6 months were lower with ofatumumab than with teriflunomide, but the groups did not differ significantly with respect to confirmed disability improvement. The results of these trials do not permit any inferences to be made about the efficacy of ofatumumab as compared with other drugs for multiple sclerosis that are considered to be more potent than teriflunomide.</div><div role="paragraph">Ofatumumab was also superior to teriflunomide in suppressing lesion activity on MRI. Lesion counts on MRI in the teriflunomide groups were higher than those previously reported in one phase 3 trial of teriflunomide as compared with placebo,<sup><a href="#core-r19" role="doc-biblioref" data-xml-rid="r19" id="body-ref-r19-2" href-manipulated="true" aria-label="Reference 19">19</a></sup> which suggests a population with more disease activity overall in the ASCLEPIOS trials, differences in the assessment methods used at the MRI analysis centers,<sup><a href="#core-r29" role="doc-biblioref" data-xml-rid="r29" id="body-ref-r29" href-manipulated="true" aria-label="Reference 29">29</a></sup> or both. Ofatumumab lowered serum concentrations of neurofilament light chain, a marker of neuroaxonal damage.<sup><a href="#core-r30" role="doc-biblioref" data-xml-rid="r30" id="body-ref-r30" href-manipulated="true" aria-label="Reference 30">30</a></sup> However, despite greater reductions in neurofilament light chain concentrations with ofatumumab than with teriflunomide, change in brain volume did not differ significantly between the two treatments. This discrepancy between two markers of tissue damage needs further analysis. Ofatumumab lowered B-cell numbers during the 4-week loading regimen, and the initial B-cell depletion was maintained by monthly injections.</div><div role="paragraph">Injection-related reactions were more frequent with ofatumumab than with placebo injections in the teriflunomide group, particularly with the first injection. Premedication was used for the first injection by less than 70% of the patients, with decreasing usage thereafter. The reason for the observed imbalance in appendicitis as an adverse event with ofatumumab is unknown, and no signal for appendicitis has been observed with ofatumumab treatment in phase 2 studies in multiple sclerosis and other autoimmune indications<sup><a href="#core-r8" role="doc-biblioref" data-xml-rid="r8 r9 r10 r11 r12" id="body-ref-r12-2" href-manipulated="true">8-12</a></sup> or with other anti-CD20 therapies in multiple sclerosis.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1 r2 r3" id="body-ref-r3-2" href-manipulated="true">1-3</a></sup></div><div role="paragraph">Ofatumumab was associated with lower annualized relapse rates than teriflunomide and showed benefit with respect to most secondary clinical and MRI end points but not confirmed disability improvement. Ofatumumab was associated with a higher frequency of injection-related systemic reactions, predominantly with the first injection, than was placebo injection. Larger and longer trials are required to determine the long-term effect and risks of ofatumumab as compared with other disease-modifying treatments, including other anti-CD20 monoclonal antibodies.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by <span class="named-content" data-type="funder">Novartis</span> Pharma.</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank the patients for their participation in and commitment to these trials; Willi Maurer, Xi Dong, Heinz Schmidli, Ekkehard Glimm, and Mouna Akacha for their innovative statistical work on the flexible-duration trial design, which reduced the time and burden for the patients enrolled; Marina Savelieva, Joseph Kahn, Gordon Graham, and Huixin Yu for the dose-finding work for subcutaneous ofatumumab in multiple sclerosis; Erik Wallstroem, Amit Khanna, Goeril Karlsson, and Nikos Sfikas for their involvement in compound selection and trial design; the clinical trial team for the conduct of the ASCLEPIOS trials; and Angela Pozo Ramajo and Liz Hambly of Oxford PharmaGenesis for medical writing assistance and copyediting assistance, respectively, with an earlier version of the manuscript.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa1917246_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa1917246/suppl_file/nejmoa1917246_protocol.pdf" download="nejmoa1917246_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa1917246_protocol.pdf" data-doi="10.1056/NEJMoa1917246">Download</a></li><li>11.69 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa1917246_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa1917246/suppl_file/nejmoa1917246_appendix.pdf" download="nejmoa1917246_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa1917246_appendix.pdf" data-doi="10.1056/NEJMoa1917246">Download</a></li><li>1.30 MB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa1917246_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa1917246/suppl_file/nejmoa1917246_disclosures.pdf" download="nejmoa1917246_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa1917246_disclosures.pdf" data-doi="10.1056/NEJMoa1917246">Download</a></li><li>905.17 KB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa1917246_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa1917246/suppl_file/nejmoa1917246_data-sharing.pdf" download="nejmoa1917246_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa1917246_data-sharing.pdf" data-doi="10.1056/NEJMoa1917246">Download</a></li><li>70.92 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. <em>N Engl J Med</em> 2017;376:221-234.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r1" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_2_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1917246&amp;key=10.1056%2FNEJMoa1601277&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28002679/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000392199100006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Ocrelizumab+versus+interferon+beta-1a+in+relapsing+multiple+sclerosis.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=221-234&amp;doi=10.1056%2FNEJMoa1601277&amp;pmid=28002679" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r1" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r4-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] therapies for multiple sclerosis. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r3-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] anti-CD20 therapies in multiple sclerosis. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. <em>N Engl J Med</em> 2008;358:676-688.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r2" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_3_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1917246&amp;key=10.1056%2FNEJMoa0706383&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18272891/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000253127700004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=B-cell+depletion+with+rituximab+in+relapsing-remitting+multiple+sclerosis.&amp;publication_year=2008&amp;journal=N+Engl+J+Med&amp;pages=676-688&amp;doi=10.1056%2FNEJMoa0706383&amp;pmid=18272891" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r2" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r4-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] therapies for multiple sclerosis. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r3-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] anti-CD20 therapies in multiple sclerosis. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. <em>N Engl J Med</em> 2017;376:209-220.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r3" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_4_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1917246&amp;key=10.1056%2FNEJMoa1606468&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28002688/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000392199100005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Ocrelizumab+versus+placebo+in+primary+progressive+multiple+sclerosis.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=209-220&amp;doi=10.1056%2FNEJMoa1606468&amp;pmid=28002688" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r3" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r4-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] therapies for multiple sclerosis. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r3-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] anti-CD20 therapies in multiple sclerosis. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Vermersch P, Czlonkowska A, Grimaldi LM, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. <em>Mult Scler</em> 2014;20:705-716.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r4" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1177/1352458513507821" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24126064/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000334865900009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Teriflunomide+versus+subcutaneous+interferon+beta-1a+in+patients+with+relapsing+multiple+sclerosis%3A+a+randomised%2C+controlled+phase+3+trial.&amp;publication_year=2014&amp;journal=Mult+Scler&amp;pages=705-716&amp;doi=10.1177%2F1352458513507821&amp;pmid=24126064" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r4" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r4-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] therapies for multiple sclerosis. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of one comparative prospective trial </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Lin TS. Ofatumumab: a novel monoclonal anti-CD20 antibody. <em>Pharmgenomics Pers Med</em> 2010;3:51-59.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r5" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23226042/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Ofatumumab%3A+a+novel+monoclonal+anti-CD20+antibody.&amp;publication_year=2010&amp;journal=Pharmgenomics+Pers+Med&amp;pages=51-59&amp;pmid=23226042" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r5" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r5-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and the larger loop of CD20 receptors. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r7" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] extent, antibody-dependent cytotoxicity. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Engelberts PJ, Voorhorst M, Schuurman J, et al. Type I CD20 antibodies recruit the B cell receptor for complement-dependent lysis of malignant B cells. <em>J Immunol</em> 2016;197:4829-4837.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.4049/jimmunol.1600811" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27807190/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000389635900032" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Type+I+CD20+antibodies+recruit+the+B+cell+receptor+for+complement-dependent+lysis+of+malignant+B+cells.&amp;publication_year=2016&amp;journal=J+Immunol&amp;pages=4829-4837&amp;doi=10.4049%2Fjimmunol.1600811&amp;pmid=27807190" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Semple KM, Gonzaléz CM, Zarr M, Austin JR, Patel V, Howard KE. Evaluation of the ability of immune humanized mice to demonstrate CD20-specific cytotoxicity induced by ofatumumab. <em>Clin Transl Sci</em> 2019;12:283-290.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/cts.12613" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30737892/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000467589700011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Evaluation+of+the+ability+of+immune+humanized+mice+to+demonstrate+CD20-specific+cytotoxicity+induced+by+ofatumumab.&amp;publication_year=2019&amp;journal=Clin+Transl+Sci&amp;pages=283-290&amp;doi=10.1111%2Fcts.12613&amp;pmid=30737892" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Bar-Or A, Grove RA, Austin DJ, et al. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: the MIRROR study. <em>Neurology</em> 2018;90(20):e1805-e1814.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1212/WNL.0000000000005516" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29695594/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000439159900009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Subcutaneous+ofatumumab+in+patients+with+relapsing-remitting+multiple+sclerosis%3A+the+MIRROR+study.&amp;publication_year=2018&amp;journal=Neurology&amp;pages=e1805-e1814&amp;doi=10.1212%2FWNL.0000000000005516&amp;pmid=29695594" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] ofatumumab can be given at lower doses </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] doses are given under medical supervision. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] sclerosis and other autoimmune indications </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Sorensen PS, Lisby S, Grove R, et al. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study. <em>Neurology</em> 2014;82:573-581.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r9" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1212/WNL.0000000000000125" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24453078/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000336498300008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety+and+efficacy+of+ofatumumab+in+relapsing-remitting+multiple+sclerosis%3A+a+phase+2+study.&amp;publication_year=2014&amp;journal=Neurology&amp;pages=573-581&amp;doi=10.1212%2FWNL.0000000000000125&amp;pmid=24453078" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r9" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] ofatumumab can be given at lower doses </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] sclerosis and other autoimmune indications </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Novartis Pharmaceuticals. Arzerra (ofatumumab) prescribing information. 2016 (<a href="https://www.novartis.us/sites/www.novartis.us/files/arzerra.pdf">https://www.novartis.us/sites/www.novartis.us/files/arzerra.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r10" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Novartis+Pharmaceuticals.+Arzerra+%28ofatumumab%29+prescribing+information.+2016+%28https%3A%2F%2Fwww.novartis.us%2Fsites%2Fwww.novartis.us%2Ffiles%2Farzerra.pdf%29." target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r10" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r12-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] leukemia and rheumatoid arthritis, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] sclerosis and other autoimmune indications </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Kurrasch R, Brown JC, Chu M, et al. Subcutaneously administered ofatumumab in rheumatoid arthritis: a phase I/II study of safety, tolerability, pharmacokinetics, and pharmacodynamics. <em>J Rheumatol</em> 2013;40:1089-1096.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r11" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3899/jrheum.121118" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23729801/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000321993800011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Subcutaneously+administered+ofatumumab+in+rheumatoid+arthritis%3A+a+phase+I%2FII+study+of+safety%2C+tolerability%2C+pharmacokinetics%2C+and+pharmacodynamics.&amp;publication_year=2013&amp;journal=J+Rheumatol&amp;pages=1089-1096&amp;doi=10.3899%2Fjrheum.121118&amp;pmid=23729801" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r11" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r12-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] leukemia and rheumatoid arthritis, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] sclerosis and other autoimmune indications </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Quattrocchi E, Østergaard M, Taylor PC, et al. Safety of repeated open-label treatment courses of intravenous ofatumumab, a human anti-CD20 monoclonal antibody, in rheumatoid arthritis: results from three clinical trials. <em>PLoS One</em> 2016;11(6):e0157961-e0157961.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r12" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.pone.0157961" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27336685/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000378389200074" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety+of+repeated+open-label+treatment+courses+of+intravenous+ofatumumab%2C+a+human+anti-CD20+monoclonal+antibody%2C+in+rheumatoid+arthritis%3A+results+from+three+clinical+trials.&amp;publication_year=2016&amp;journal=PLoS+One&amp;pages=e0157961-e0157961&amp;doi=10.1371%2Fjournal.pone.0157961&amp;pmid=27336685" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r12" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r12-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] leukemia and rheumatoid arthritis, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] sclerosis and other autoimmune indications </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Kähäri L, Fair-Mäkelä R, Auvinen K, et al. Transcytosis route mediates rapid delivery of intact antibodies to draining lymph nodes. <em>J Clin Invest</em> 2019;129:3086-3102.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1172/JCI125740" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31232704/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000478076500017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Transcytosis+route+mediates+rapid+delivery+of+intact+antibodies+to+draining+lymph+nodes.&amp;publication_year=2019&amp;journal=J+Clin+Invest&amp;pages=3086-3102&amp;doi=10.1172%2FJCI125740&amp;pmid=31232704" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Theil D, Smith P, Huck C, et al. Imaging mass cytometry and single-cell genomics reveal differential depletion and repletion of B-cell populations following ofatumumab treatment in cynomolgus monkeys. <em>Front Immunol</em> 2019;10:1340-1340.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3389/fimmu.2019.01340" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31281311/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000472217000001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Imaging+mass+cytometry+and+single-cell+genomics+reveal+differential+depletion+and+repletion+of+B-cell+populations+following+ofatumumab+treatment+in+cynomolgus+monkeys.&amp;publication_year=2019&amp;journal=Front+Immunol&amp;pages=1340-1340&amp;doi=10.3389%2Ffimmu.2019.01340&amp;pmid=31281311" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Genentech. Ocrevus (ocrelizumab) prescribing information. 2020 (<a href="https://www.gene.com/download/pdf/ocrevus_prescribing.pdf">https://www.gene.com/download/pdf/ocrevus_prescribing.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Genentech.+Ocrevus+%28ocrelizumab%29+prescribing+information.+2020+%28https%3A%2F%2Fwww.gene.com%2Fdownload%2Fpdf%2Focrevus_prescribing.pdf%29." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Leppert D. Comparison of the B-cell recovery time following discontinuation of anti-CD20 therapies. <em>ECTRIMS Online Library</em>. October 25, 2017 (<a href="https://onlinelibrary.ectrims-congress.eu/ectrims/2017/ACTRIMS-ECTRIMS2017/199644/david.leppert.comparison.of.the.b-cell.recovery.time.following.discontinuation.html">https://onlinelibrary.ectrims-congress.eu/ectrims/2017/ACTRIMS-ECTRIMS2017/199644/david.leppert.comparison.of.the.b-cell.recovery.time.following.discontinuation.html</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comparison+of+the+B-cell+recovery+time+following+discontinuation+of+anti-CD20+therapies&amp;publication_year=2017" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Roll P, Palanichamy A, Kneitz C, Dorner T, Tony H-P. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. <em>Arthritis Rheum</em> 2006;54:2377-2386.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/art.22019" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16869000/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Regeneration+of+B+cell+subsets+after+transient+B+cell+depletion+using+anti-CD20+antibodies+in+rheumatoid+arthritis.&amp;publication_year=2006&amp;journal=Arthritis+Rheum&amp;pages=2377-2386&amp;doi=10.1002%2Fart.22019&amp;pmid=16869000" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Confavreux C, O’Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. <em>Lancet Neurol</em> 2014;13:247-256.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r19-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1474-4422(13)70308-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24461574/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000332264300008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Oral+teriflunomide+for+patients+with+relapsing+multiple+sclerosis+%28TOWER%29%3A+a+randomised%2C+double-blind%2C+placebo-controlled%2C+phase+3+trial.&amp;publication_year=2014&amp;journal=Lancet+Neurol&amp;pages=247-256&amp;doi=10.1016%2FS1474-4422%2813%2970308-9&amp;pmid=24461574" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">O’Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. <em>N Engl J Med</em> 2011;365:1293-1303.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r19" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_20_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1917246&amp;key=10.1056%2FNEJMoa1014656&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21991951/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000295578700007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Randomized+trial+of+oral+teriflunomide+for+relapsing+multiple+sclerosis.&amp;publication_year=2011&amp;journal=N+Engl+J+Med&amp;pages=1293-1303&amp;doi=10.1056%2FNEJMoa1014656&amp;pmid=21991951" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r19" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] reducing T-cell and B-cell activation. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of teriflunomide as compared with placebo, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">Fogarty E, Schmitz S, Tubridy N, Walsh C, Barry M. Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: systematic review and network meta-analysis. <em>Mult Scler Relat Disord</em> 2016;9:23-30.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.msard.2016.06.001" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27645339/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000384862000007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comparative+efficacy+of+disease-modifying+therapies+for+patients+with+relapsing+remitting+multiple+sclerosis%3A+systematic+review+and+network+meta-analysis.&amp;publication_year=2016&amp;journal=Mult+Scler+Relat+Disord&amp;pages=23-30&amp;doi=10.1016%2Fj.msard.2016.06.001&amp;pmid=27645339" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">Buron MD, Chalmer TA, Sellebjerg F, et al. Comparative effectiveness of teriflunomide and dimethyl fumarate: a nationwide cohort study. <em>Neurology</em> 2019;92(16):e1811-e1820.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1212/WNL.0000000000007314" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30877188/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000480759500002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comparative+effectiveness+of+teriflunomide+and+dimethyl+fumarate%3A+a+nationwide+cohort+study.&amp;publication_year=2019&amp;journal=Neurology&amp;pages=e1811-e1820&amp;doi=10.1212%2FWNL.0000000000007314&amp;pmid=30877188" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content">Kalincik T, Kubala Havrdova E, Horakova D, et al. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. <em>J Neurol Neurosurg Psychiatry</em> 2019;90:458-468.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/jnnp-2018-319831" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30636699/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000471115600018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comparison+of+fingolimod%2C+dimethyl+fumarate+and+teriflunomide+for+multiple+sclerosis.&amp;publication_year=2019&amp;journal=J+Neurol+Neurosurg+Psychiatry&amp;pages=458-468&amp;doi=10.1136%2Fjnnp-2018-319831&amp;pmid=30636699" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="r23" class="citations"><div class="citation"><div class="citation-content">International Conference on Harmonisation. ICH harmonized tripartite guideline: Guideline for Good Clinical Practice. <em>J Postgrad Med</em> 2001;47:45-50.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/11590294/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=ICH+harmonized+tripartite+guideline%3A+Guideline+for+Good+Clinical+Practice.&amp;publication_year=2001&amp;journal=J+Postgrad+Med&amp;pages=45-50&amp;pmid=11590294" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="r24" class="citations"><div class="citation"><div class="citation-content">World Medical Association. WMA Declaration of Helsinki: ethical principles for medical research involving human subjects. 2006 (<a href="https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/">https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=WMA+Declaration+of+Helsinki%3A+ethical+principles+for+medical+research+involving+human+subjects&amp;publication_year=2006" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="r25" class="citations"><div class="citation"><div class="citation-content">Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. <em>Ann Neurol</em> 2011;69:292-302.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/ana.22366" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21387374/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000288284900012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Diagnostic+criteria+for+multiple+sclerosis%3A+2010+revisions+to+the+McDonald+criteria.&amp;publication_year=2011&amp;journal=Ann+Neurol&amp;pages=292-302&amp;doi=10.1002%2Fana.22366&amp;pmid=21387374" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="r26" class="citations"><div class="citation"><div class="citation-content">Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. <em>Neurology</em> 2014;83:278-286.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1212/WNL.0000000000000560" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24871874/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000340190800014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Defining+the+clinical+course+of+multiple+sclerosis%3A+the+2013+revisions.&amp;publication_year=2014&amp;journal=Neurology&amp;pages=278-286&amp;doi=10.1212%2FWNL.0000000000000560&amp;pmid=24871874" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="r27" class="citations"><div class="citation"><div class="citation-content">Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). <em>Neurology</em> 1983;33:1444-1452.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1212/WNL.33.11.1444" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/6685237/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1983RP86600009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Rating+neurologic+impairment+in+multiple+sclerosis%3A+an+expanded+disability+status+scale+%28EDSS%29.&amp;publication_year=1983&amp;journal=Neurology&amp;pages=1444-1452&amp;doi=10.1212%2FWNL.33.11.1444&amp;pmid=6685237" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="r28" class="citations"><div class="citation"><div class="citation-content">U.S. Department of Health and Human Services. <em>Common Terminology Criteria for Adverse Events (CTCAE)</em>. 2017 (<a href="https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Common+Terminology+Criteria+for+Adverse+Events+%28CTCAE%29&amp;publication_year=2017" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="r29" class="citations"><div class="citation"><div class="citation-content">Schach S, Scholz M, Wolinsky JS, Kappos L. Pooled historical MRI data as a basis for research in multiple sclerosis — a statistical evaluation. <em>Mult Scler</em> 2007;13:509-516.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r29"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1177/1352458506069537" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17463073/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000246845000009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pooled+historical+MRI+data+as+a+basis+for+research+in+multiple+sclerosis+%E2%80%94+a+statistical+evaluation.&amp;publication_year=2007&amp;journal=Mult+Scler&amp;pages=509-516&amp;doi=10.1177%2F1352458506069537&amp;pmid=17463073" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="r30" class="citations"><div class="citation"><div class="citation-content">Disanto G, Barro C, Benkert P, et al. Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. <em>Ann Neurol</em> 2017;81:857-870.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r30"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/ana.24954" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28512753/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000403795200011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Serum+neurofilament+light%3A+a+biomarker+of+neuronal+damage+in+multiple+sclerosis.&amp;publication_year=2017&amp;journal=Ann+Neurol&amp;pages=857-870&amp;doi=10.1002%2Fana.24954&amp;pmid=28512753" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/383/6"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">383</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">6</span></span> • <span property="datePublished">August 6, 2020</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">546</span>-<span property="pageEnd">557</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2020 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: August 5, 2020</div><div><b class="core-label">Published in issue</b>: August 6, 2020</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/multiple-sclerosis" alt="View article keyword Multiple Sclerosis" data-interactiontype="article_recirculation_click">Multiple Sclerosis</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Stephen L.</span> <span property="familyName">Hauser</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-4932-4001" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-4932-4001</a></span>, <span property="author" typeof="Person"><span property="givenName">Amit</span> <span property="familyName">Bar-Or</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jeffrey A.</span> <span property="familyName">Cohen</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Giancarlo</span> <span property="familyName">Comi</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jorge</span> <span property="familyName">Correale</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Patricia K.</span> <span property="familyName">Coyle</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Anne H.</span> <span property="familyName">Cross</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jerome</span> <span property="familyName">de Seze</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">David</span> <span property="familyName">Leppert</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Xavier</span> <span property="familyName">Montalban</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Krzysztof</span> <span property="familyName">Selmaj</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Heinz</span> <span property="familyName">Wiendl</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Cecile</span> <span property="familyName">Kerloeguen</span>, <span property="honorificSuffix">M.Sc.</span></span>, <span property="author" typeof="Person"><span property="givenName">Roman</span> <span property="familyName">Willi</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Bingbing</span> <span property="familyName">Li</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Algirdas</span> <span property="familyName">Kakarieka</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Davorka</span> <span property="familyName">Tomic</span>, <span property="honorificSuffix">D.V.M.</span></span>, <span property="author" typeof="Person"><span property="givenName">Alexandra</span> <span property="familyName">Goodyear</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Ratnakar</span> <span property="familyName">Pingili</span>, <span property="honorificSuffix">M.B., B.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Dieter A.</span> <span property="familyName">Häring</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Krishnan</span> <span property="familyName">Ramanathan</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Martin</span> <span property="familyName">Merschhemke</span>, <span property="honorificSuffix">M.D.</span></span>, and <span property="author" typeof="Person"><span property="givenName">Ludwig</span> <span property="familyName">Kappos</span>, <span property="honorificSuffix">M.D.</span></span>, for <span property="author" typeof="Person">the ASCLEPIOS I and ASCLEPIOS II Trial Groups<sup><a href="#fn2" role="doc-noteref">*</a></sup></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From the UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco (S.L.H.); the Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.B.-O.); the Department of Neurology, Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland (J.A.C.); the Institute of Experimental Neurology and Multiple Sclerosis Center IRCCS, San Raffaele Hospital, Milan (G.C.); the Department of Neurology, Fleni, Buenos Aires (J.C.); the Department of Neurology, Stony Brook University, Stony Brook, NY (P.K.C.); Washington University School of Medicine, St. Louis (A.H.C.); the University Hospital of Strasburg and Clinical Investigation Center INSERM 1434, Strasburg, France (J.S.); University Hospital Basel (D.L.), Novartis Pharma (C.K., R.W., A.K., D.T., D.A.H., K.R., M.M.), and the Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel (L.K.) — all in Basel, Switzerland; the Department of Neurology–Neuroimmunology, Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d’Hebron, Barcelona (X.M.); the University of Warmia and Mazury, Olsztyn, and the Center of Neurology, Lodz — both in Poland (K.S.); the Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany (H.W.); and Novartis Pharmaceuticals, East Hanover, NJ (B.L., A.G., R.P.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Address reprint requests to Dr. Hauser at the UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, 675 Nelson Rising Ln., San Francisco, CA 94158, or at <a href="mailto:stephen.hauser@ucsf.edu">stephen.hauser@ucsf.edu</a>; or to Dr. Kappos at the Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland, or at <a href="mailto:kapposl-pa@usb.ch">kapposl-pa@usb.ch</a>.</div><div role="doc-footnote"><div id="fn2" role="paragraph">*A complete list of investigators in the ASCLEPIOS I and ASCLEPIOS II Trial Groups is provided in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org.</div></div><div role="doc-footnote"><div id="fn1" role="paragraph">Drs. Hauser and Kappos contributed equally to this article.</div></div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">496</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa1917246" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="65210769-81ca-a45a-6d62-d91fc82b4b90"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=87719212" style="display:inline-block;">
                <img alt="Article has an altmetric score of 946" src="https://badges.altmetric.com/?size=320&amp;score=946&amp;types=mabctwfd" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=87719212">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_65210769-81ca-a45a-6d62-d91fc82b4b90" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=87719212&amp;tab=news">
          Picked up by <b>117</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=87719212&amp;tab=blogs">
          Blogged by <b>3</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #9f79f2;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=87719212&amp;tab=policy-documents">
          Referenced in <b>1</b> policy sources
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=87719212&amp;tab=twitter">
          Posted by <b>115</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #f27700;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=87719212&amp;tab=patents">
          Referenced in <b>7</b> patents
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=87719212&amp;tab=facebook">
          On <b>4</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #958899;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=87719212&amp;tab=wikipedia">
          Referenced in <b>3</b> Wikipedia pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #A1E3E4;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=87719212&amp;tab=guidelines">
          Referenced in <b>1</b> clinical guideline sources
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>637</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d63f5a762df1db-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa1917246"> <input type="hidden" name="downloadFileName" value="csp_383_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2020.383.issue-6%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa1917246%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="496" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Bruno M. Barros, </li><li class="list-inline-item cited-by__entry__author">Marcelo G. Correia, </li><li class="list-inline-item cited-by__entry__author">Bernardo R. Tura, </li><li class="list-inline-item cited-by__entry__author">Carlos S. Magliano, </li></ul><span class="cited-by__entry__title">Cost-Utility Analysis and Efficiency Frontier of Drugs Available in Brazil for the Treatment of Relapsing-Remitting Multiple Sclerosis, </span><span class="cited-by__entry__series-title">Value in Health Regional Issues, </span><span class="cited-by__entry__volume"><strong>48</strong>, </span><span class="cited-by__entry__page-range">(101092), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.vhri.2025.101092" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.vhri.2025.101092</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.vhri.2025.101092" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Turlough Montague, </li><li class="list-inline-item cited-by__entry__author">Ivonne Lichtenberg, </li><li class="list-inline-item cited-by__entry__author">Emily Cheung, </li><li class="list-inline-item cited-by__entry__author">Katharine Kline, </li><li class="list-inline-item cited-by__entry__author">Varitsara Mangkorntongsakul, </li><li class="list-inline-item cited-by__entry__author">Yuuki Kang, </li><li class="list-inline-item cited-by__entry__author">Michael Barnett, </li><li class="list-inline-item cited-by__entry__author">Stephen Reddel, </li><li class="list-inline-item cited-by__entry__author">Judith Spies, </li><li class="list-inline-item cited-by__entry__author">John Parratt, </li></ul><span class="cited-by__entry__title">Seronegative spondyloarthritis as a complication of anti-CD20 monoclonal antibody treatment in multiple sclerosis, </span><span class="cited-by__entry__series-title">Multiple Sclerosis and Related Disorders, </span><span class="cited-by__entry__volume"><strong>99</strong>, </span><span class="cited-by__entry__page-range">(106425), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.msard.2025.106425" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.msard.2025.106425</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.msard.2025.106425" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Si-Ting Wu, </li><li class="list-inline-item cited-by__entry__author">Tian-Xiang Zhang, </li><li class="list-inline-item cited-by__entry__author">Zhirui Liu, </li><li class="list-inline-item cited-by__entry__author">Xueting An, </li><li class="list-inline-item cited-by__entry__author">Xiaoshan Du, </li><li class="list-inline-item cited-by__entry__author">Shu Yang, </li><li class="list-inline-item cited-by__entry__author">Ti Wu, </li><li class="list-inline-item cited-by__entry__author">Guanju Di, </li><li class="list-inline-item cited-by__entry__author">Jingshi Song, </li><li class="list-inline-item cited-by__entry__author">Bin Feng, </li><li class="list-inline-item cited-by__entry__author">Chunyang Wang, </li><li class="list-inline-item cited-by__entry__author">Chao Zhang, </li></ul><span class="cited-by__entry__title">NEK2 regulates B cell function and the severity of experimental autoimmune encephalomyelitis, </span><span class="cited-by__entry__series-title">Journal of Neuroinflammation, </span><span class="cited-by__entry__volume"><strong>22</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1186/s12974-025-03472-w" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1186/s12974-025-03472-w</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1186/s12974-025-03472-w" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Mario García-Domínguez, </li></ul><span class="cited-by__entry__title">Neuroinflammation: Mechanisms, Dual Roles, and Therapeutic Strategies in Neurological Disorders, </span><span class="cited-by__entry__series-title">Current Issues in Molecular Biology, </span><span class="cited-by__entry__volume"><strong>47</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(417), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3390/cimb47060417" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3390/cimb47060417</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3390/cimb47060417" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Barbara Polistena, </li><li class="list-inline-item cited-by__entry__author">Anna Maria Provenzano, </li><li class="list-inline-item cited-by__entry__author">Caterina Rizzi, </li><li class="list-inline-item cited-by__entry__author">Elena Colombo, </li><li class="list-inline-item cited-by__entry__author">Roberto Bergamaschi, </li></ul><span class="cited-by__entry__title">Cost-Consequences of Cladribine Tablets for the Treatment of Highly Active Relapsing–Remitting Multiple Sclerosis in Italy, </span><span class="cited-by__entry__series-title">Neurology and Therapy, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1007/s40120-025-00761-7" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1007/s40120-025-00761-7</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1007/s40120-025-00761-7" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Ali Maisam Afzali, </li><li class="list-inline-item cited-by__entry__author">Thomas Korn, </li></ul><span class="cited-by__entry__title">The role of the adaptive immune system in the initiation and persistence of multiple sclerosis, </span><span class="cited-by__entry__series-title">Seminars in Immunology, </span><span class="cited-by__entry__volume"><strong>78</strong>, </span><span class="cited-by__entry__page-range">(101947), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.smim.2025.101947" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.smim.2025.101947</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.smim.2025.101947" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Isra Omar, </li><li class="list-inline-item cited-by__entry__author">Ahmed Alakhras, </li><li class="list-inline-item cited-by__entry__author">Samahir Mutwali, </li><li class="list-inline-item cited-by__entry__author">Moiz Bakhiet, </li></ul><span class="cited-by__entry__title">Navigating multiple sclerosis: From clinical categories to clinical management, </span><span class="cited-by__entry__series-title">Brain Disorders, </span><span class="cited-by__entry__volume"><strong>18</strong>, </span><span class="cited-by__entry__page-range">(100235), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.dscb.2025.100235" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.dscb.2025.100235</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.dscb.2025.100235" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Ludwig Kappos, </li><li class="list-inline-item cited-by__entry__author">Sean Yiu, </li><li class="list-inline-item cited-by__entry__author">Frank Dahlke, </li><li class="list-inline-item cited-by__entry__author">Timothy Coetzee, </li><li class="list-inline-item cited-by__entry__author">Gary R. Cutter, </li><li class="list-inline-item cited-by__entry__author">Steven Yuen, </li><li class="list-inline-item cited-by__entry__author">Ulrike Bonati, </li><li class="list-inline-item cited-by__entry__author">Fred D. Lublin, </li></ul><span class="cited-by__entry__title">Composite Confirmed Disability Worsening/Progression Is a Useful Clinical Endpoint for Multiple Sclerosis Clinical Trials, </span><span class="cited-by__entry__series-title">Neurology, </span><span class="cited-by__entry__volume"><strong>104</strong>, </span><span class="cited-by__entry__issue">10, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1212/WNL.0000000000213558" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1212/WNL.0000000000213558</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1212/WNL.0000000000213558" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Brit Ellen Rød, </li><li class="list-inline-item cited-by__entry__author">Einar A Høgestøl, </li><li class="list-inline-item cited-by__entry__author">Øivind Torkildsen, </li><li class="list-inline-item cited-by__entry__author">Kjetil Bjørnevik, </li><li class="list-inline-item cited-by__entry__author">Jon Michael Gran, </li><li class="list-inline-item cited-by__entry__author">Mathias H Øverås, </li><li class="list-inline-item cited-by__entry__author">Marton König, </li><li class="list-inline-item cited-by__entry__author">Kjell-Morten Myhr, </li><li class="list-inline-item cited-by__entry__author">Stig Wergeland, </li><li class="list-inline-item cited-by__entry__author">Gro O Nygaard, </li></ul><span class="cited-by__entry__title">Comparative effectiveness of rituximab and cladribine in relapsing–remitting multiple sclerosis: A target trial emulation, </span><span class="cited-by__entry__series-title">Multiple Sclerosis Journal, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1177/13524585251342727" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1177/13524585251342727</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1177/13524585251342727" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Amber Salter, </li><li class="list-inline-item cited-by__entry__author">Samantha Lancia, </li><li class="list-inline-item cited-by__entry__author">Kaarina Kowalec, </li><li class="list-inline-item cited-by__entry__author">Kathryn Fitzgerald, </li><li class="list-inline-item cited-by__entry__author">Ruth Ann Marrie, </li></ul><span class="cited-by__entry__title">Comorbidities, safety and persistence in phase III clinical trials in multiple sclerosis, </span><span class="cited-by__entry__series-title">Journal of Neurology, Neurosurgery &amp; Psychiatry, </span><span class="cited-by__entry__page-range">(jnnp-2024-335710), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1136/jnnp-2024-335710" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1136/jnnp-2024-335710</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1136/jnnp-2024-335710" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2020.383.issue-6%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa1917246%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa1917246" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa1917246" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa1917246.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1917246_f1.jpg"><img src="/cms/10.1056/NEJMoa1917246/asset/fb4af6fb-f4bc-4618-856f-84a6dc6f5677/assets/images/large/nejmoa1917246_f1.jpg" height="3438" width="2276" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Confirmed Disability Worsening and Improvement.</div><div class="notes"><div role="doc-footnote">Shown are Kaplan–Meier estimates of the percentages of patients with disability worsening confirmed at 3 months (Panel A) and at 6 months (Panel B) and of patients with disability improvement (i.e., lessening of disability) confirmed at 6 months (Panel C) in time-to-event analyses in the combined trial populations. Disability worsening confirmed at 3 months or 6 months was defined as an increase from baseline in the Expanded Disability Status Scale (EDSS) score (on a scale from 0 to 10.0, with higher scores indicating worse disability) that was sustained for at least 3 or 6 months. For patients with a baseline EDSS score of 0, an increase in the EDSS score of at least 1.5 points was required; for patients with a baseline EDSS score of 1.0 to 5.0, the criterion was an increase of at least 1.0 point; and for patients with a baseline EDSS score of at least 5.5 points, the criterion was an increase of at least 0.5 points. Disability improvement confirmed at 6 months was defined as a decrease from baseline in the EDSS score that was sustained for at least 6 months. For patients with baseline EDSS scores of 2.0 to 6.0 points, a decrease of at least 1.0 point was required; for patients with baseline EDSS scores of 6.5 to 9.0 points, a decrease of at least 0.5 points was required. The numbers shown on the curves represent Kaplan–Meier estimates of the risk of the event at 24 months (marked by the vertical dashed line). The insets show the same data on an expanded y axis.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1917246_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1917246_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa1917246/asset/46cf2105-2e46-4832-a4e5-c4e358c5a928/assets/images/large/nejmoa1917246_t1.jpg" height="2750" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders" colspan="2"><span>ASCLEPIOS I Trial</span></th><th class="txxr-borders" colspan="2"><span>ASCLEPIOS II Trial</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Ofatumumab<br>(N=465)</th><th class="xxxx-borders">Teriflunomide<br>(N=462)</th><th class="xxxx-borders">Ofatumumab<br>(N=481)</th><th class="xxxr-borders">Teriflunomide<br>(N=474)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Age — yr<a href="#core-t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">38.9±8.8</td><td class="xxxx-borders shading">37.8±9.0</td><td class="xxxx-borders shading">38.0±9.3</td><td class="xxxr-borders shading">38.2±9.5</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Female sex — no. (%)</td><td class="xxxx-borders">318 (68.4)</td><td class="xxxx-borders">317 (68.6)</td><td class="xxxx-borders">319 (66.3)</td><td class="xxxr-borders">319 (67.3)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Type of multiple sclerosis — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Relapsing–remitting</td><td class="xxxx-borders">438 (94.2)</td><td class="xxxx-borders">434 (93.9)</td><td class="xxxx-borders">452 (94.0)</td><td class="xxxr-borders">450 (94.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Secondary progressive</td><td class="xxxx-borders shading">27 (5.8)</td><td class="xxxx-borders shading">28 (6.1)</td><td class="xxxx-borders shading">29 (6.0)</td><td class="xxxr-borders shading">24 (5.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Time since symptom onset — yr</td><td class="xxxx-borders">8.36±6.84</td><td class="xxxx-borders">8.18±7.21</td><td class="xxxx-borders">8.20±7.40</td><td class="xxxr-borders">8.19±7.38</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Time since diagnosis — yr</td><td class="xxxx-borders shading">5.77±6.05</td><td class="xxxx-borders shading">5.64±6.20</td><td class="xxxx-borders shading">5.59±6.38</td><td class="xxxr-borders shading">5.48±6.00</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">No previous disease-modifying therapy — no. (%)</td><td class="xxxx-borders">191 (41.1)</td><td class="xxxx-borders">182 (39.4)</td><td class="xxxx-borders">195 (40.5)</td><td class="xxxr-borders">181 (38.2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Previous disease-modifying therapy — no. (%)<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Any interferon beta</td><td class="xxxx-borders">189 (40.6)</td><td class="xxxx-borders">193 (41.8)</td><td class="xxxx-borders">197 (41.0)</td><td class="xxxr-borders">193 (40.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Glatiramer acetate</td><td class="xxxx-borders shading">124 (26.7)</td><td class="xxxx-borders shading">106 (22.9)</td><td class="xxxx-borders shading">118 (24.5)</td><td class="xxxr-borders shading">149 (31.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Dimethyl fumarate</td><td class="xxxx-borders">36 (7.7)</td><td class="xxxx-borders">37 (8.0)</td><td class="xxxx-borders">36 (7.5)</td><td class="xxxr-borders">44 (9.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Teriflunomide</td><td class="xxxx-borders shading">8 (1.7)</td><td class="xxxx-borders shading">6 (1.3)</td><td class="xxxx-borders shading">13 (2.7)</td><td class="xxxr-borders shading">9 (1.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Daclizumab</td><td class="xxxx-borders">5 (1.1)</td><td class="xxxx-borders">12 (2.6)</td><td class="xxxx-borders">8 (1.7)</td><td class="xxxr-borders">7 (1.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Fingolimod</td><td class="xxxx-borders shading">10 (2.2)</td><td class="xxxx-borders shading">15 (3.2)</td><td class="xxxx-borders shading">13 (2.7)</td><td class="xxxr-borders shading">10 (2.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Natalizumab</td><td class="xxxx-borders">31 (6.7)</td><td class="xxxx-borders">36 (7.8)</td><td class="xxxx-borders">26 (5.4)</td><td class="xxxr-borders">20 (4.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Any B-cell therapy<a href="#core-t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">2 (0.4)</td><td class="xxxx-borders shading">3 (0.6)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Laquinimod</td><td class="xxxx-borders">5 (1.1)</td><td class="xxxx-borders">4 (0.9)</td><td class="xxxx-borders">2 (0.4)</td><td class="xxxr-borders">7 (1.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Other disease-modifying therapy<a href="#core-t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">52 (11.2)</td><td class="xxxx-borders shading">65 (14.1)</td><td class="xxxx-borders shading">68 (14.1)</td><td class="xxxr-borders shading">81 (17.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">No. of relapses in previous 12 mo</td><td class="xxxx-borders">1.2±0.6</td><td class="xxxx-borders">1.3±0.7</td><td class="xxxx-borders">1.3±0.7</td><td class="xxxr-borders">1.3±0.7</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">No. of relapses in previous &gt;12–24 mo</td><td class="xxxx-borders shading">0.9±0.9</td><td class="xxxx-borders shading">0.9±1.2</td><td class="xxxx-borders shading">0.7±0.9</td><td class="xxxr-borders shading">0.8±1.0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">EDSS score<a href="#core-t1fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders">2.97±1.36</td><td class="xxxx-borders">2.94±1.36</td><td class="xxxx-borders">2.90±1.34</td><td class="xxxr-borders">2.86±1.37</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">No. of gadolinium-enhancing lesions per T1-weighted MRI scan</td><td class="xxxx-borders shading">1.7±4.9</td><td class="xxxx-borders shading">1.2±2.6</td><td class="xxxx-borders shading">1.6±4.1</td><td class="xxxr-borders shading">1.5±4.1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Absence of gadolinium-enhancing lesions on T1-weighted MRI — no. (%)</td><td class="xxxx-borders">291 (62.6)</td><td class="xxxx-borders">293 (63.4)</td><td class="xxxx-borders">270 (56.1)</td><td class="xxxr-borders">291 (61.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Volume of lesions on T2-weighted MRI — cm<sup>3</sup></td><td class="xxxx-borders shading">13.2±13.3</td><td class="xxxx-borders shading">13.1±14.6</td><td class="xxxx-borders shading">14.3±14.2</td><td class="xxxr-borders shading">12.0±13.0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Neurofilament light chain concentration — pg/ml</td><td class="xxxx-borders">13.3±13.2</td><td class="xxxx-borders">11.7±9.3</td><td class="xxxx-borders">14.7±18.2</td><td class="xxxr-borders">13.4±14.0</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02 shading" data-xml-align="left">Normalized brain volume — cm<sup>3</sup></td><td class="xbxx-borders shading">1439±81</td><td class="xbxx-borders shading">1442±79</td><td class="xbxx-borders shading">1441±77</td><td class="xbxr-borders shading">1446±77</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">Plus–minus values are means ±SD. Data on time since symptom onset were missing for 1 patient in the teriflunomide group in the ASCLEPIOS II trial. Data on the number of relapses in the previous more than 12 to 24 months were missing for 1 patient in each group in the ASCLEPIOS II trial. Data on the Expanded Disability Status Scale (EDSS) score were missing for 1 patient in the teriflunomide group in each trial. Data on the number of gadolinium-enhancing lesions per T1-weighted magnetic resonance imaging (MRI) scan were missing for 11 patients in the ofatumumab group and for 10 in the teriflunomide group in the ASCLEPIOS I trial and for 12 in the ofatumumab group and 4 in the teriflunomide group in the ASCLEPIOS II trial. Data on the volume of lesions on T2-weighted MRI were missing for 4 patients in the ofatumumab group and for 5 in the teriflunomide group in the ASCLEPIOS I trial and for 8 in the ofatumumab group and 1 in the teriflunomide group in the ASCLEPIOS II trial. Data on neurofilament light chain concentration were missing for 18 patients in the ofatumumab group and for 41 in the teriflunomide group in the ASCLEPIOS I trial and for 35 in the ofatumumab group and 42 in the teriflunomide group in the ASCLEPIOS II trial. Data on normalized brain volume were missing for 5 patients in the ofatumumab group and for 8 in the teriflunomide group in the ASCLEPIOS I trial and for 12 in the ofatumumab group and 1 in the teriflunomide group in the ASCLEPIOS II trial.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">Age at baseline was calculated from the date of the first administration of trial drug and the birth year (no exact birth date was captured for reasons of data privacy). Eligibility for trial entry was assessed at the screening visit.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">A patient could be counted in multiple categories.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t1fn4" role="paragraph" data-to-manipulate="true">In the ASCLEPIOS I trial, rituximab had been received by 1 patient in the teriflunomide group, and ocrelizumab had been received by 2 patients in the ofatumumab group and by 2 in the teriflunomide group.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t1fn5" role="paragraph" data-to-manipulate="true">This category includes all medications that were recorded by the investigator as a disease-modifying therapy but were not included in the listed medications.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="core-t1fn6" role="paragraph" data-to-manipulate="true">Scores on the Expanded Disability Status Scale (EDSS) range from 0 to 10.0, with higher scores indicating worse disability. The score at baseline was defined as the score at the last assessment before the first dose administration of trial drug. Eligibility was assessed at the screening visit.</div></div></div></figcaption></a><figcaption><div class="caption">Demographic and Disease Characteristics of the Patients at Baseline (Full Analysis Set).<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1917246_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1917246_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa1917246/asset/c66c4b2b-55db-48e2-8435-2a3436f6b4be/assets/images/large/nejmoa1917246_t2.jpg" height="3314" width="2615" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">End Point</th><th class="txxx-borders" colspan="3"><span>ASCLEPIOS I Trial</span></th><th class="txxx-borders" colspan="3"><span>ASCLEPIOS II Trial</span></th><th class="txxr-borders" colspan="3"><span>Pooled Trials</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Ofatumumab<br>(N=465)</th><th class="xxxx-borders">Teriflunomide<br>(N=462)</th><th class="xxxx-borders">P<br>Value</th><th class="xxxx-borders">Ofatumumab<br>(N=481)</th><th class="xxxx-borders">Teriflunomide<br>(N=474)</th><th class="xxxx-borders">P<br>Value</th><th class="xxxx-borders">Ofatumumab<br>(N=946)</th><th class="xxxx-borders">Teriflunomide<br>(N=936)</th><th class="xxxr-borders">P<br>Value</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Primary end point</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Total no. of relapses</td><td class="xxxx-borders">90</td><td class="xxxx-borders">177</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">95</td><td class="xxxx-borders">198</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">No. of patients evaluated</td><td class="xxxx-borders shading">454</td><td class="xxxx-borders shading">452</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">469</td><td class="xxxx-borders shading">469</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Adjusted annualized relapse rate (95% CI)</td><td class="xxxx-borders">0.11<br>(0.09 to 0.14)</td><td class="xxxx-borders">0.22<br>(0.18 to 0.26)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">0.10<br>(0.08 to 0.13)</td><td class="xxxx-borders">0.25<br>(0.21 to 0.30)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Difference (95% CI)</td><td class="xxxx-borders shading" colspan="2">−0.11 (−0.16 to −0.06)</td><td class="xxxx-borders shading">&lt;0.001</td><td class="xxxx-borders shading" colspan="2">−0.15 (−0.20 to −0.09)</td><td class="xxxx-borders shading">&lt;0.001</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Rate ratio (95% CI)</td><td class="xxxx-borders" colspan="2">0.49 (0.37 to 0.65)</td><td class="xxxx-borders">&lt;0.001</td><td class="xxxx-borders" colspan="2">0.42 (0.31 to 0.56)</td><td class="xxxx-borders">&lt;0.001</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Disability-related end points</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Disability worsening confirmed at 3 mo</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">No. of events during the trial/no. of patients</td><td class="xxxx-borders shading">45/465</td><td class="xxxx-borders shading">63/459</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">43/479</td><td class="xxxx-borders shading">62/472</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">88/944</td><td class="xxxx-borders shading">125/931</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Kaplan–Meier estimate at 24 mo — %</td><td class="xxxx-borders">11.3</td><td class="xxxx-borders">15.4</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">10.5</td><td class="xxxx-borders">14.6</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">10.9</td><td class="xxxx-borders">15.0</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Hazard ratio (95% CI)</td><td class="xxxx-borders shading" colspan="2">0.65 (0.45 to 0.96)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading" colspan="2">0.66 (0.45 to 0.97)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading" colspan="2">0.66 (0.50 to 0.86)</td><td class="xxxr-borders shading">0.002</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Disability worsening confirmed at 6 mo</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">No. of events during the trial/no. of patients</td><td class="xxxx-borders shading">35/465</td><td class="xxxx-borders shading">53/459</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">36/479</td><td class="xxxx-borders shading">46/472</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">71/944</td><td class="xxxx-borders shading">99/931</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Kaplan–Meier estimate at 24 mo — %</td><td class="xxxx-borders">8.2</td><td class="xxxx-borders">13.0</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">8.0</td><td class="xxxx-borders">10.9</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">8.1</td><td class="xxxx-borders">12.0</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Hazard ratio (95% CI)</td><td class="xxxx-borders shading" colspan="2">0.61 (0.40 to 0.93)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading" colspan="2">0.76 (0.49 to 1.17)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading" colspan="2">0.68 (0.50 to 0.92)</td><td class="xxxr-borders shading">0.01</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Disability improvement confirmed at 6 mo</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">No. of events during the trial/no. of patients</td><td class="xxxx-borders shading">33/375</td><td class="xxxx-borders shading">26/363</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">41/374</td><td class="xxxx-borders shading">27/360</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">74/749</td><td class="xxxx-borders shading">53/723</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Kaplan–Meier estimate at 24 mo — %</td><td class="xxxx-borders">9.7</td><td class="xxxx-borders">8.2</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">12.3</td><td class="xxxx-borders">8.1</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">11.0</td><td class="xxxx-borders">8.1</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Hazard ratio (95% CI)</td><td class="xxxx-borders shading" colspan="2">1.19 (0.71 to 1.98)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading" colspan="2">1.52 (0.93 to 2.47)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading" colspan="2">1.35 (0.95 to 1.92)</td><td class="xxxr-borders shading">0.09</td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><b>MRI-related end points</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Gd+ lesions on T1-weighted MRI</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">No. of patients evaluated</td><td class="xxxx-borders">432</td><td class="xxxx-borders">422</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">439</td><td class="xxxx-borders">434</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Mean no. of lesions per scan (95% CI)</td><td class="xxxx-borders shading">0.01<br>(0.01 to 0.02)</td><td class="xxxx-borders shading">0.45<br>(0.36 to 0.58)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0.03<br>(0.02 to 0.05)</td><td class="xxxx-borders shading">0.51<br>(0.40 to 0.66)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Rate ratio (95% CI)</td><td class="xxxx-borders" colspan="2">0.03 (0.01 to 0.05)</td><td class="xxxx-borders">&lt;0.001</td><td class="xxxx-borders" colspan="2">0.06 (0.04 to 0.10)</td><td class="xxxx-borders">&lt;0.001</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">New or enlarging lesions on T2-weighted MRI by end of trial</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">No. of patients evaluated</td><td class="xxxx-borders">440</td><td class="xxxx-borders">431</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">448</td><td class="xxxx-borders">443</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Mean no. of lesions per yr (95% CI)</td><td class="xxxx-borders shading">0.72<br>(0.61 to 0.85)</td><td class="xxxx-borders shading">4.00<br>(3.47 to 4.61)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0.64<br>(0.55 to 0.75)</td><td class="xxxx-borders shading">4.15<br>(3.64 to 4.74)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Rate ratio (95% CI)</td><td class="xxxx-borders" colspan="2">0.18 (0.15 to 0.22)</td><td class="xxxx-borders">&lt;0.001</td><td class="xxxx-borders" colspan="2">0.15 (0.13 to 0.19)</td><td class="xxxx-borders">&lt;0.001</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlr-borders hanging02 shading" colspan="10">Brain-volume change</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">No. of patients evaluated</td><td class="xxxx-borders">418</td><td class="xxxx-borders">409</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">437</td><td class="xxxx-borders">434</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Annual rate of change (95% CI) — %<a href="#core-t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">−0.28<br>(−0.34 to −0.22)</td><td class="xxxx-borders shading">−0.35<br>(−0.41 to −0.29)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">−0.29<br>(−0.35 to −0.23)</td><td class="xxxx-borders shading">−0.35<br>(−0.42 to −0.29)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Difference (95% CI) — percentage points</td><td class="xxxx-borders" colspan="2">0.07 (−0.02 to 0.15)</td><td class="xxxx-borders">0.12</td><td class="xxxx-borders" colspan="2">0.07 (−0.02 to 0.15)</td><td class="xxxx-borders">0.13</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Serum NfL concentration</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">At 3 mo</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">No. of patients evaluated</td><td class="xxxx-borders shading">430</td><td class="xxxx-borders shading">404</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">425</td><td class="xxxx-borders shading">423</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Geometric mean (95% CI) — pg/ml</td><td class="xxxx-borders">8.8<br>(8.5 to 9.1)</td><td class="xxxx-borders">9.4<br>(9.1 to 9.8)</td><td class="xxxx-borders">0.01</td><td class="xxxx-borders">8.9<br>(8.6 to 9.2)</td><td class="xxxx-borders">10.0<br>(9.7 to 10.4)</td><td class="xxxx-borders">&lt;0.001</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">At 12 mo</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">No. of patients evaluated</td><td class="xxxx-borders">414</td><td class="xxxx-borders">399</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">406</td><td class="xxxx-borders">406</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Geometric mean (95% CI) — pg/ml</td><td class="xxxx-borders shading">7.0<br>(6.7 to 7.3)</td><td class="xxxx-borders shading">9.6<br>(9.2 to 10.1)</td><td class="xxxx-borders shading">&lt;0.001</td><td class="xxxx-borders shading">7.1<br>(6.8 to 7.4)</td><td class="xxxx-borders shading">9.5<br>(9.1 to 10.0)</td><td class="xxxx-borders shading">&lt;0.001</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">At 24 mo</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">No. of patients evaluated</td><td class="xxxx-borders shading">371</td><td class="xxxx-borders shading">350</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">345</td><td class="xxxx-borders shading">349</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left">Geometric mean (95% CI) — pg/ml</td><td class="xbxx-borders">6.9<br>(6.6 to 7.2)</td><td class="xbxx-borders">9.0<br>(8.6 to 9.5)</td><td class="xbxx-borders">&lt;0.001</td><td class="xbxx-borders">6.8<br>(6.5 to 7.1)</td><td class="xbxx-borders">9.0<br>(8.6 to 9.4)</td><td class="xbxx-borders">&lt;0.001</td><td class="xbxx-borders">&nbsp;</td><td class="xbxx-borders">&nbsp;</td><td class="xbxr-borders">&nbsp;</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">All difference values, rate ratios, and hazard ratios are for ofatumumab compared with teriflunomide. Gd+ denotes gadolinium enhancing, and NfL neurofilament light chain.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t2fn2" role="paragraph" data-to-manipulate="true">The annual rate of brain-volume change was estimated according to the slope from a random-coefficient model, on the basis of assessment of the percentage change from baseline in brain volume performed at month 12, month 24, and the end of the trial.</div></div></div></figcaption></a><figcaption><div class="caption">Clinical, MRI, and Biomarker End Points (Full Analysis Set).<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1917246_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t3"><figure class="table"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1917246_t3.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa1917246/asset/73e332d2-7649-483e-8c12-8b09e8140168/assets/images/large/nejmoa1917246_t3.jpg" height="1751" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Variable</th><th class="txxx-borders" colspan="2"><span>ASCLEPIOS I Trial</span></th><th class="txxr-borders" colspan="2"><span>ASCLEPIOS II Trial</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Ofatumumab<br>(N=465)</th><th class="xxxx-borders">Teriflunomide<br>(N=462)</th><th class="xxxx-borders">Ofatumumab<br>(N=481)</th><th class="xxxr-borders">Teriflunomide<br>(N=474)</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="4"><span>number of patients (percent)</span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Any adverse event</td><td class="xxxx-borders shading">382 (82.2)</td><td class="xxxx-borders shading">380 (82.3)</td><td class="xxxx-borders shading">409 (85.0)</td><td class="xxxr-borders shading">408 (86.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Adverse event leading to treatment discontinuation</td><td class="xxxx-borders">27 (5.8)</td><td class="xxxx-borders">24 (5.2)</td><td class="xxxx-borders">27 (5.6)</td><td class="xxxr-borders">25 (5.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Infection</td><td class="xxxx-borders shading">229 (49.2)</td><td class="xxxx-borders shading">238 (51.5)</td><td class="xxxx-borders shading">259 (53.8)</td><td class="xxxr-borders shading">255 (53.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Injection-related systemic reaction<a href="#core-t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">75 (16.1)</td><td class="xxxx-borders">76 (16.5)</td><td class="xxxx-borders">116 (24.1)</td><td class="xxxr-borders">64 (13.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Serious adverse event</td><td class="xxxx-borders shading">48 (10.3)</td><td class="xxxx-borders shading">38 (8.2)</td><td class="xxxx-borders shading">38 (7.9)</td><td class="xxxr-borders shading">36 (7.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Serious infection<a href="#core-t3fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">12 (2.6)</td><td class="xxxx-borders">7 (1.5)</td><td class="xxxx-borders">12 (2.5)</td><td class="xxxr-borders">10 (2.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Serious injection-related reaction</td><td class="xxxx-borders shading">2 (0.4)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Neoplasm<a href="#core-t3fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">3 (0.6)</td><td class="xxxx-borders">3 (0.6)</td><td class="xxxx-borders">2 (0.4)</td><td class="xxxr-borders">1 (0.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02 shading" data-xml-align="left">Death</td><td class="xbxx-borders shading">0</td><td class="xbxx-borders shading">0</td><td class="xbxx-borders shading">0</td><td class="xbxr-borders shading">1 (0.2)<a href="#core-t3fn5" role="doc-noteref">¶</a></td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t3fn1" role="paragraph" data-to-manipulate="true">Shown is the number of patients with at least one event and the percentage of all patients in each group. Adverse events were coded according to the preferred terms in the <i>Medical Dictionary for Regulatory Activities</i>, version 20.0. Relapses of multiple sclerosis that were reported as adverse events were excluded.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t3fn2" role="paragraph" data-to-manipulate="true">Only reactions or symptoms that occurred within 24 hours after injection are included (i.e., time to onset of reaction, ≤24 hours).</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t3fn3" role="paragraph" data-to-manipulate="true">Serious infections and infestations that were reported in the ofatumumab group were appendicitis (in 8 patients), gastroenteritis (in 3), urinary tract infection (in 3), influenza (in 2), and cystitis, escherichia urinary tract infection, kidney infection, lower respiratory tract infection, neutropenic sepsis, osteomyelitis, pneumonia, upper respiratory tract infection, urosepsis, and viral respiratory tract infection (in 1 patient each). Serious infections and infestations that were reported in the teriflunomide group were appendicitis (in 2 patients), urinary tract infection (in 2), and abscess of the sweat glands, campylobacter infection, cystitis, influenza pneumonia, osteomyelitis, paronychia, peritonitis, pneumonia, postoperative abscess, salpingo-oophoritis, sepsis, tickborne viral encephalitis, and viral infection (in 1 patient each).</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t3fn4" role="paragraph" data-to-manipulate="true">Neoplasms that were reported in patients receiving ofatumumab were one case of malignant melanoma in situ (time to onset, 39 days), one case of invasive breast carcinoma (time to onset, 149 days), one case of recurrent non-Hodgkin’s lymphoma (time to onset, 31 days), and two cases of basal-cell carcinoma (time to onset, 120 and 258 days). Neoplasms that were reported in patients receiving teriflunomide were one case of fibrosarcoma (time to onset, 652 days), one case of cervix carcinoma (time to onset, 341 days), and two cases of basal-cell carcinoma (time to onset, 8 and 401 days). None of the malignant events were considered by the investigator to be related to trial treatment, and no cluster of neoplasms was identified.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t3fn5" role="paragraph" data-to-manipulate="true">The cause of death was aortic dissection.</div></div></div></figcaption></a><figcaption><div class="caption">Adverse Events (Safety Population).<a href="#core-t3fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t3"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1917246_t3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa1917246</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. <em>N Engl J Med</em> 2017;376:221-234.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r1-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_2_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1917246&amp;key=10.1056%2FNEJMoa1601277&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28002679/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000392199100006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Ocrelizumab+versus+interferon+beta-1a+in+relapsing+multiple+sclerosis.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=221-234&amp;doi=10.1056%2FNEJMoa1601277&amp;pmid=28002679" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r1-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r4-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] therapies for multiple sclerosis. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r3-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] anti-CD20 therapies in multiple sclerosis. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. <em>N Engl J Med</em> 2008;358:676-688.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r2-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_3_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1917246&amp;key=10.1056%2FNEJMoa0706383&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18272891/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000253127700004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=B-cell+depletion+with+rituximab+in+relapsing-remitting+multiple+sclerosis.&amp;publication_year=2008&amp;journal=N+Engl+J+Med&amp;pages=676-688&amp;doi=10.1056%2FNEJMoa0706383&amp;pmid=18272891" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r2-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r4-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] therapies for multiple sclerosis. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r3-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] anti-CD20 therapies in multiple sclerosis. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. <em>N Engl J Med</em> 2017;376:209-220.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r3-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_4_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1917246&amp;key=10.1056%2FNEJMoa1606468&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28002688/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000392199100005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Ocrelizumab+versus+placebo+in+primary+progressive+multiple+sclerosis.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=209-220&amp;doi=10.1056%2FNEJMoa1606468&amp;pmid=28002688" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r3-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r4-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] therapies for multiple sclerosis. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r3-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] anti-CD20 therapies in multiple sclerosis. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Vermersch P, Czlonkowska A, Grimaldi LM, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. <em>Mult Scler</em> 2014;20:705-716.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r4-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1177/1352458513507821" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24126064/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000334865900009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Teriflunomide+versus+subcutaneous+interferon+beta-1a+in+patients+with+relapsing+multiple+sclerosis%3A+a+randomised%2C+controlled+phase+3+trial.&amp;publication_year=2014&amp;journal=Mult+Scler&amp;pages=705-716&amp;doi=10.1177%2F1352458513507821&amp;pmid=24126064" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r4-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r4-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] therapies for multiple sclerosis. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of one comparative prospective trial </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Lin TS. Ofatumumab: a novel monoclonal anti-CD20 antibody. <em>Pharmgenomics Pers Med</em> 2010;3:51-59.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r5-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23226042/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Ofatumumab%3A+a+novel+monoclonal+anti-CD20+antibody.&amp;publication_year=2010&amp;journal=Pharmgenomics+Pers+Med&amp;pages=51-59&amp;pmid=23226042" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r5-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r5-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and the larger loop of CD20 receptors. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r7" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] extent, antibody-dependent cytotoxicity. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Engelberts PJ, Voorhorst M, Schuurman J, et al. Type I CD20 antibodies recruit the B cell receptor for complement-dependent lysis of malignant B cells. <em>J Immunol</em> 2016;197:4829-4837.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.4049/jimmunol.1600811" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27807190/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000389635900032" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Type+I+CD20+antibodies+recruit+the+B+cell+receptor+for+complement-dependent+lysis+of+malignant+B+cells.&amp;publication_year=2016&amp;journal=J+Immunol&amp;pages=4829-4837&amp;doi=10.4049%2Fjimmunol.1600811&amp;pmid=27807190" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Semple KM, Gonzaléz CM, Zarr M, Austin JR, Patel V, Howard KE. Evaluation of the ability of immune humanized mice to demonstrate CD20-specific cytotoxicity induced by ofatumumab. <em>Clin Transl Sci</em> 2019;12:283-290.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/cts.12613" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30737892/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000467589700011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Evaluation+of+the+ability+of+immune+humanized+mice+to+demonstrate+CD20-specific+cytotoxicity+induced+by+ofatumumab.&amp;publication_year=2019&amp;journal=Clin+Transl+Sci&amp;pages=283-290&amp;doi=10.1111%2Fcts.12613&amp;pmid=30737892" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Bar-Or A, Grove RA, Austin DJ, et al. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: the MIRROR study. <em>Neurology</em> 2018;90(20):e1805-e1814.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1212/WNL.0000000000005516" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29695594/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000439159900009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Subcutaneous+ofatumumab+in+patients+with+relapsing-remitting+multiple+sclerosis%3A+the+MIRROR+study.&amp;publication_year=2018&amp;journal=Neurology&amp;pages=e1805-e1814&amp;doi=10.1212%2FWNL.0000000000005516&amp;pmid=29695594" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] ofatumumab can be given at lower doses </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] doses are given under medical supervision. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] sclerosis and other autoimmune indications </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Sorensen PS, Lisby S, Grove R, et al. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study. <em>Neurology</em> 2014;82:573-581.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r9-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1212/WNL.0000000000000125" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24453078/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000336498300008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety+and+efficacy+of+ofatumumab+in+relapsing-remitting+multiple+sclerosis%3A+a+phase+2+study.&amp;publication_year=2014&amp;journal=Neurology&amp;pages=573-581&amp;doi=10.1212%2FWNL.0000000000000125&amp;pmid=24453078" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r9-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] ofatumumab can be given at lower doses </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] sclerosis and other autoimmune indications </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Novartis Pharmaceuticals. Arzerra (ofatumumab) prescribing information. 2016 (<a href="https://www.novartis.us/sites/www.novartis.us/files/arzerra.pdf">https://www.novartis.us/sites/www.novartis.us/files/arzerra.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r10-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Novartis+Pharmaceuticals.+Arzerra+%28ofatumumab%29+prescribing+information.+2016+%28https%3A%2F%2Fwww.novartis.us%2Fsites%2Fwww.novartis.us%2Ffiles%2Farzerra.pdf%29." target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r10-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r12-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] leukemia and rheumatoid arthritis, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] sclerosis and other autoimmune indications </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Kurrasch R, Brown JC, Chu M, et al. Subcutaneously administered ofatumumab in rheumatoid arthritis: a phase I/II study of safety, tolerability, pharmacokinetics, and pharmacodynamics. <em>J Rheumatol</em> 2013;40:1089-1096.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r11-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3899/jrheum.121118" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23729801/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000321993800011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Subcutaneously+administered+ofatumumab+in+rheumatoid+arthritis%3A+a+phase+I%2FII+study+of+safety%2C+tolerability%2C+pharmacokinetics%2C+and+pharmacodynamics.&amp;publication_year=2013&amp;journal=J+Rheumatol&amp;pages=1089-1096&amp;doi=10.3899%2Fjrheum.121118&amp;pmid=23729801" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r11-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r12-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] leukemia and rheumatoid arthritis, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] sclerosis and other autoimmune indications </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Quattrocchi E, Østergaard M, Taylor PC, et al. Safety of repeated open-label treatment courses of intravenous ofatumumab, a human anti-CD20 monoclonal antibody, in rheumatoid arthritis: results from three clinical trials. <em>PLoS One</em> 2016;11(6):e0157961-e0157961.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r12-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.pone.0157961" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27336685/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000378389200074" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety+of+repeated+open-label+treatment+courses+of+intravenous+ofatumumab%2C+a+human+anti-CD20+monoclonal+antibody%2C+in+rheumatoid+arthritis%3A+results+from+three+clinical+trials.&amp;publication_year=2016&amp;journal=PLoS+One&amp;pages=e0157961-e0157961&amp;doi=10.1371%2Fjournal.pone.0157961&amp;pmid=27336685" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r12-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r12-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] leukemia and rheumatoid arthritis, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] sclerosis and other autoimmune indications </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Kähäri L, Fair-Mäkelä R, Auvinen K, et al. Transcytosis route mediates rapid delivery of intact antibodies to draining lymph nodes. <em>J Clin Invest</em> 2019;129:3086-3102.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1172/JCI125740" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31232704/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000478076500017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Transcytosis+route+mediates+rapid+delivery+of+intact+antibodies+to+draining+lymph+nodes.&amp;publication_year=2019&amp;journal=J+Clin+Invest&amp;pages=3086-3102&amp;doi=10.1172%2FJCI125740&amp;pmid=31232704" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Theil D, Smith P, Huck C, et al. Imaging mass cytometry and single-cell genomics reveal differential depletion and repletion of B-cell populations following ofatumumab treatment in cynomolgus monkeys. <em>Front Immunol</em> 2019;10:1340-1340.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3389/fimmu.2019.01340" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31281311/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000472217000001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Imaging+mass+cytometry+and+single-cell+genomics+reveal+differential+depletion+and+repletion+of+B-cell+populations+following+ofatumumab+treatment+in+cynomolgus+monkeys.&amp;publication_year=2019&amp;journal=Front+Immunol&amp;pages=1340-1340&amp;doi=10.3389%2Ffimmu.2019.01340&amp;pmid=31281311" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Genentech. Ocrevus (ocrelizumab) prescribing information. 2020 (<a href="https://www.gene.com/download/pdf/ocrevus_prescribing.pdf">https://www.gene.com/download/pdf/ocrevus_prescribing.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Genentech.+Ocrevus+%28ocrelizumab%29+prescribing+information.+2020+%28https%3A%2F%2Fwww.gene.com%2Fdownload%2Fpdf%2Focrevus_prescribing.pdf%29." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Leppert D. Comparison of the B-cell recovery time following discontinuation of anti-CD20 therapies. <em>ECTRIMS Online Library</em>. October 25, 2017 (<a href="https://onlinelibrary.ectrims-congress.eu/ectrims/2017/ACTRIMS-ECTRIMS2017/199644/david.leppert.comparison.of.the.b-cell.recovery.time.following.discontinuation.html">https://onlinelibrary.ectrims-congress.eu/ectrims/2017/ACTRIMS-ECTRIMS2017/199644/david.leppert.comparison.of.the.b-cell.recovery.time.following.discontinuation.html</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comparison+of+the+B-cell+recovery+time+following+discontinuation+of+anti-CD20+therapies&amp;publication_year=2017" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Roll P, Palanichamy A, Kneitz C, Dorner T, Tony H-P. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. <em>Arthritis Rheum</em> 2006;54:2377-2386.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/art.22019" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16869000/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Regeneration+of+B+cell+subsets+after+transient+B+cell+depletion+using+anti-CD20+antibodies+in+rheumatoid+arthritis.&amp;publication_year=2006&amp;journal=Arthritis+Rheum&amp;pages=2377-2386&amp;doi=10.1002%2Fart.22019&amp;pmid=16869000" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Confavreux C, O’Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. <em>Lancet Neurol</em> 2014;13:247-256.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r19-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1474-4422(13)70308-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24461574/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000332264300008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Oral+teriflunomide+for+patients+with+relapsing+multiple+sclerosis+%28TOWER%29%3A+a+randomised%2C+double-blind%2C+placebo-controlled%2C+phase+3+trial.&amp;publication_year=2014&amp;journal=Lancet+Neurol&amp;pages=247-256&amp;doi=10.1016%2FS1474-4422%2813%2970308-9&amp;pmid=24461574" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">O’Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. <em>N Engl J Med</em> 2011;365:1293-1303.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r19-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_20_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1917246&amp;key=10.1056%2FNEJMoa1014656&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21991951/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000295578700007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Randomized+trial+of+oral+teriflunomide+for+relapsing+multiple+sclerosis.&amp;publication_year=2011&amp;journal=N+Engl+J+Med&amp;pages=1293-1303&amp;doi=10.1056%2FNEJMoa1014656&amp;pmid=21991951" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r19-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] reducing T-cell and B-cell activation. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of teriflunomide as compared with placebo, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">Fogarty E, Schmitz S, Tubridy N, Walsh C, Barry M. Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: systematic review and network meta-analysis. <em>Mult Scler Relat Disord</em> 2016;9:23-30.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.msard.2016.06.001" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27645339/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000384862000007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comparative+efficacy+of+disease-modifying+therapies+for+patients+with+relapsing+remitting+multiple+sclerosis%3A+systematic+review+and+network+meta-analysis.&amp;publication_year=2016&amp;journal=Mult+Scler+Relat+Disord&amp;pages=23-30&amp;doi=10.1016%2Fj.msard.2016.06.001&amp;pmid=27645339" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">Buron MD, Chalmer TA, Sellebjerg F, et al. Comparative effectiveness of teriflunomide and dimethyl fumarate: a nationwide cohort study. <em>Neurology</em> 2019;92(16):e1811-e1820.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1212/WNL.0000000000007314" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30877188/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000480759500002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comparative+effectiveness+of+teriflunomide+and+dimethyl+fumarate%3A+a+nationwide+cohort+study.&amp;publication_year=2019&amp;journal=Neurology&amp;pages=e1811-e1820&amp;doi=10.1212%2FWNL.0000000000007314&amp;pmid=30877188" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content">Kalincik T, Kubala Havrdova E, Horakova D, et al. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. <em>J Neurol Neurosurg Psychiatry</em> 2019;90:458-468.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/jnnp-2018-319831" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30636699/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000471115600018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comparison+of+fingolimod%2C+dimethyl+fumarate+and+teriflunomide+for+multiple+sclerosis.&amp;publication_year=2019&amp;journal=J+Neurol+Neurosurg+Psychiatry&amp;pages=458-468&amp;doi=10.1136%2Fjnnp-2018-319831&amp;pmid=30636699" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="core-r23" class="citations"><div class="citation"><div class="citation-content">International Conference on Harmonisation. ICH harmonized tripartite guideline: Guideline for Good Clinical Practice. <em>J Postgrad Med</em> 2001;47:45-50.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/11590294/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=ICH+harmonized+tripartite+guideline%3A+Guideline+for+Good+Clinical+Practice.&amp;publication_year=2001&amp;journal=J+Postgrad+Med&amp;pages=45-50&amp;pmid=11590294" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="core-r24" class="citations"><div class="citation"><div class="citation-content">World Medical Association. WMA Declaration of Helsinki: ethical principles for medical research involving human subjects. 2006 (<a href="https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/">https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=WMA+Declaration+of+Helsinki%3A+ethical+principles+for+medical+research+involving+human+subjects&amp;publication_year=2006" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="core-r25" class="citations"><div class="citation"><div class="citation-content">Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. <em>Ann Neurol</em> 2011;69:292-302.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/ana.22366" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21387374/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000288284900012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Diagnostic+criteria+for+multiple+sclerosis%3A+2010+revisions+to+the+McDonald+criteria.&amp;publication_year=2011&amp;journal=Ann+Neurol&amp;pages=292-302&amp;doi=10.1002%2Fana.22366&amp;pmid=21387374" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="core-r26" class="citations"><div class="citation"><div class="citation-content">Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. <em>Neurology</em> 2014;83:278-286.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1212/WNL.0000000000000560" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24871874/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000340190800014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Defining+the+clinical+course+of+multiple+sclerosis%3A+the+2013+revisions.&amp;publication_year=2014&amp;journal=Neurology&amp;pages=278-286&amp;doi=10.1212%2FWNL.0000000000000560&amp;pmid=24871874" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="core-r27" class="citations"><div class="citation"><div class="citation-content">Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). <em>Neurology</em> 1983;33:1444-1452.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1212/WNL.33.11.1444" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/6685237/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1983RP86600009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Rating+neurologic+impairment+in+multiple+sclerosis%3A+an+expanded+disability+status+scale+%28EDSS%29.&amp;publication_year=1983&amp;journal=Neurology&amp;pages=1444-1452&amp;doi=10.1212%2FWNL.33.11.1444&amp;pmid=6685237" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="core-r28" class="citations"><div class="citation"><div class="citation-content">U.S. Department of Health and Human Services. <em>Common Terminology Criteria for Adverse Events (CTCAE)</em>. 2017 (<a href="https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Common+Terminology+Criteria+for+Adverse+Events+%28CTCAE%29&amp;publication_year=2017" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="core-r29" class="citations"><div class="citation"><div class="citation-content">Schach S, Scholz M, Wolinsky JS, Kappos L. Pooled historical MRI data as a basis for research in multiple sclerosis — a statistical evaluation. <em>Mult Scler</em> 2007;13:509-516.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r29"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1177/1352458506069537" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17463073/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000246845000009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pooled+historical+MRI+data+as+a+basis+for+research+in+multiple+sclerosis+%E2%80%94+a+statistical+evaluation.&amp;publication_year=2007&amp;journal=Mult+Scler&amp;pages=509-516&amp;doi=10.1177%2F1352458506069537&amp;pmid=17463073" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="core-r30" class="citations"><div class="citation"><div class="citation-content">Disanto G, Barro C, Benkert P, et al. Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. <em>Ann Neurol</em> 2017;81:857-870.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r30"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/ana.24954" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28512753/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000403795200011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Serum+neurofilament+light%3A+a+biomarker+of+neuronal+damage+in+multiple+sclerosis.&amp;publication_year=2017&amp;journal=Ann+Neurol&amp;pages=857-870&amp;doi=10.1002%2Fana.24954&amp;pmid=28512753" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 9, 2025</div><div class="nejm-widget_item"><div><span> New York</span></div><div><span>Gastroenterology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/726363/gi-hospitalist-south-shore-university-hospital-northwell-health/?query=fjwp&amp;rid=3059">GI Hospitalist - South Shore University Hospital, Northwell Health</a></div></div><div class="nejm-widget_item"><div><span> Hackensack, New Jersey</span></div><div><span>Neurology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/882542/neuro-oncologist-jtcc-hackensack/?query=fjwp&amp;rid=5696">Neuro-Oncologist - JTCC Hackensack</a></div></div><div class="nejm-widget_item"><div><span> Dublin, California</span></div><div><span>Hematology / Oncology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/888188/hematologist-oncologist-epic-care-dublin/?query=fjwp&amp;rid=5696">Hematologist/Oncologist - Epic Care Dublin</a></div></div><div class="nejm-widget_item"><div><span> Bellingham, Washington State</span></div><div><span>Internal Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/889004/come-live-the-outdoors-in-beautiful-bellingham/?query=fjwf&amp;rid=14710">Come Live the Outdoors in Beautiful Bellingham</a></div></div><div class="nejm-widget_item"><div><span> Modesto, California</span></div><div><span>Obstetrics &amp; Gynecology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/889314/physician-ob-gyn-maternal-and-fetal-medicine-modesto-ca-/?query=fjwf&amp;rid=845677">Physician, OB/GYN: Maternal and Fetal Medicine (Modesto, CA)</a></div></div><div class="nejm-widget_item"><div><span> Peoria, Illinois</span></div><div><span>Obstetrics &amp; Gynecology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/890289/ob-gyn/?query=fjwf&amp;rid=346908">OB/GYN</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128720&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejmai%2Fregister%2Faifallpdf24%3Fpromo%3DOAFQF4NA%26query%3Dcm-rr%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Daifallpdf24&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa1917246&amp;pubId=41289706&amp;placeholderId=101337&amp;productId=1007" target="_blank"><img src="/sda/128720/NEJ-AI-Fall24-300x250---002.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d63f5a762df1db-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d63f5a762df1db-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d63f5a762df1db-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$073193224$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$073193224$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$073193224$--></div></div><div class="mlt-body"><!--?lit$073193224$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$073193224$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$073193224$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$073193224$-->May 15, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2415985?query=recirc_Semantic" target="_self">Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis</a></div><div class="mlt-article-authors"><!--?lit$073193224$-->J. Oh and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$073193224$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$073193224$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$073193224$-->Aug 25, 2022</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2201904?query=recirc_Semantic" target="_self">Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis</a></div><div class="mlt-article-authors"><!--?lit$073193224$-->L. Steinman and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/editorial" target="_self"><!--?lit$073193224$-->Editorial</a> <span class="mlt-article-site-label"><!--?lit$073193224$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$073193224$-->May 15, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMe2503891?query=recirc_Semantic" target="_self">Progress toward Mitigating Disability Progression in Multiple Sclerosis</a></div><div class="mlt-article-authors"><!--?lit$073193224$-->P.A. Calabresi</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$073193224$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$073193224$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$073193224$-->May 15, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2415988?query=recirc_Semantic" target="_self">Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis</a></div><div class="mlt-article-authors"><!--?lit$073193224$-->R.J. Fox and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$073193224$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$073193224$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$073193224$-->Feb 15, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2309439?query=recirc_Semantic" target="_self">Inhibition of CD40L with Frexalimab in Multiple Sclerosis</a></div><div class="mlt-article-authors"><!--?lit$073193224$-->P. Vermersch and Others</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa1917246?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa1917246" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa1917246.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa1917246"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Ofatumumab versus Teriflunomide in Multiple Sclerosis</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMoa1911023" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Zika Virus Disease and Pregnancy Outcomes in Colombia</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMoa1604037" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Zika Virus Disease in Colombia — Preliminary Report</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1917246_f1.jpg"><img src="/cms/10.1056/NEJMoa1917246/asset/fb4af6fb-f4bc-4618-856f-84a6dc6f5677/assets/images/large/nejmoa1917246_f1.jpg" height="3438" width="2276" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Confirmed Disability Worsening and Improvement.</div><div class="notes"><div role="doc-footnote">Shown are Kaplan–Meier estimates of the percentages of patients with disability worsening confirmed at 3 months (Panel A) and at 6 months (Panel B) and of patients with disability improvement (i.e., lessening of disability) confirmed at 6 months (Panel C) in time-to-event analyses in the combined trial populations. Disability worsening confirmed at 3 months or 6 months was defined as an increase from baseline in the Expanded Disability Status Scale (EDSS) score (on a scale from 0 to 10.0, with higher scores indicating worse disability) that was sustained for at least 3 or 6 months. For patients with a baseline EDSS score of 0, an increase in the EDSS score of at least 1.5 points was required; for patients with a baseline EDSS score of 1.0 to 5.0, the criterion was an increase of at least 1.0 point; and for patients with a baseline EDSS score of at least 5.5 points, the criterion was an increase of at least 0.5 points. Disability improvement confirmed at 6 months was defined as a decrease from baseline in the EDSS score that was sustained for at least 6 months. For patients with baseline EDSS scores of 2.0 to 6.0 points, a decrease of at least 1.0 point was required; for patients with baseline EDSS scores of 6.5 to 9.0 points, a decrease of at least 0.5 points was required. The numbers shown on the curves represent Kaplan–Meier estimates of the risk of the event at 24 months (marked by the vertical dashed line). The insets show the same data on an expanded y axis.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Demographic and Disease Characteristics of the Patients at Baseline (Full Analysis Set).<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Clinical, MRI, and Biomarker End Points (Full Analysis Set).<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t3" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 3</div><div class="fv__item__description"><figcaption><div class="caption">Adverse Events (Safety Population).<a href="#fv-t3fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/383/6" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 383 No. 6</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Aug 06, 2020</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa1604037" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Zika Virus Disease in Colombia — Preliminary Report</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">O. Pacheco and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Aug 06, 2020</span></li><li data-toggle="tooltip" data-original-title="Visual Abstract" class="issue-item_meta-item"><span role="img" aria-label="Visual Abstract" tabindex="0" class="issue-item_visualAbstract"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-visual"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa1915932" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Subcutaneous or Transvenous Defibrillator Therapy</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">R.E. Knops and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Aug 06, 2020</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2016638" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">D.R. Boulware and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa1917246%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa1917246&amp;pubId=41289706&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa1917246%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa1917246&amp;pubId=41289706&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id03786007038371614" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d63f5a762df1db-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d63f5a762df1db-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d63f5a762df1db-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d63f5a762df1db-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d63f5a762df1db-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d63f5a762df1db-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d63f5a762df1db-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d63f5a762df1db-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d63f5a762df1db-SJC"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d63f5a762df1db-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d63f5a6bd1f1db',t:'MTc0OTUzMTAyMi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d63f5a6bd1f1db&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script><div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div>

        
        
    

<div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa1917246?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=1-10"></script><div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><jkx-ezgxqetdmmgt></jkx-ezgxqetdmmgt><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><iframe name="captureIFrame_ue9v5lpmkkluprkvprx17wyupskr2r3vruucz69v" data-transactionid="ue9v5lpmkkluprkvprx17wyupskr2r3vruucz69v" id="captureIFrame_ue9v5lpmkkluprkvprx17wyupskr2r3vruucz69v" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="ue9v5lpmkkluprkvprx17wyupskr2r3vruucz69v" target="captureIFrame_ue9v5lpmkkluprkvprx17wyupskr2r3vruucz69v" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_ue9v5lpmkkluprkvprx17wyupskr2r3vruucz69v" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_ue9v5lpmkkluprkvprx17wyupskr2r3vruucz69v" name="capture_screen"><input id="capture_signIn_js_version_ue9v5lpmkkluprkvprx17wyupskr2r3vruucz69v" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_ue9v5lpmkkluprkvprx17wyupskr2r3vruucz69v" name="js_version"><input id="capture_signIn_transactionId_ue9v5lpmkkluprkvprx17wyupskr2r3vruucz69v" data-capturefield="undefined" value="ue9v5lpmkkluprkvprx17wyupskr2r3vruucz69v" type="hidden" class="capture_transactionId_ue9v5lpmkkluprkvprx17wyupskr2r3vruucz69v" name="capture_transactionId"><input id="capture_signIn_form_ue9v5lpmkkluprkvprx17wyupskr2r3vruucz69v" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_ue9v5lpmkkluprkvprx17wyupskr2r3vruucz69v" name="form"><input id="capture_signIn_flow_ue9v5lpmkkluprkvprx17wyupskr2r3vruucz69v" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_ue9v5lpmkkluprkvprx17wyupskr2r3vruucz69v" name="flow"><input id="capture_signIn_client_id_ue9v5lpmkkluprkvprx17wyupskr2r3vruucz69v" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_ue9v5lpmkkluprkvprx17wyupskr2r3vruucz69v" name="client_id"><input id="capture_signIn_redirect_uri_ue9v5lpmkkluprkvprx17wyupskr2r3vruucz69v" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_ue9v5lpmkkluprkvprx17wyupskr2r3vruucz69v" name="redirect_uri"><input id="capture_signIn_response_type_ue9v5lpmkkluprkvprx17wyupskr2r3vruucz69v" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_ue9v5lpmkkluprkvprx17wyupskr2r3vruucz69v" name="response_type"><input id="capture_signIn_flow_version_ue9v5lpmkkluprkvprx17wyupskr2r3vruucz69v" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_ue9v5lpmkkluprkvprx17wyupskr2r3vruucz69v" name="flow_version"><input id="capture_signIn_settings_version_ue9v5lpmkkluprkvprx17wyupskr2r3vruucz69v" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_ue9v5lpmkkluprkvprx17wyupskr2r3vruucz69v" name="settings_version"><input id="capture_signIn_locale_ue9v5lpmkkluprkvprx17wyupskr2r3vruucz69v" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_ue9v5lpmkkluprkvprx17wyupskr2r3vruucz69v" name="locale"><input id="capture_signIn_recaptcha_version_ue9v5lpmkkluprkvprx17wyupskr2r3vruucz69v" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_ue9v5lpmkkluprkvprx17wyupskr2r3vruucz69v" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div></body></html>